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ABSTRACT
Triple Negative Breast Cancer (TNBC) is highly invasive and metastatic with
approximately 15% of patients developing liver metastases. The primary treatment of metastatic
TNBC is chemotherapy, however, there is an increased chance of resistance to this therapeutic
technique. If Breast Cancer Liver Metastasis (BCLM) is left untreated most patients survive only
4 to 8 months with a very rare 5-year survival. Therefore, it is imperative to analyze markers and
molecular pathways that TNBC cells use to progress, invade, and metastasize to the liver. The
aim of this study was to examine the overexpression of angiopoietin-like 4 (ANGPTL4) in
TNBC cells in vitro and in vivo.
Experimentally, ANGPTL4 mGFP was overexpressed in the MDA-MB-231(TNBC) cell
line using lentiviral-mediated transduction. This expression was then confirmed using western
blot analysis, ELISA, and fluorescence microscopy.
The intracellular localization of ANGPTL4, Tat-interactive protein p60 (Tip60) and
Aurora Kinase A (AURKA) were evaluated by subcellular fractionation, western blot analysis,
and immunofluorescence microscopy. This study showed that ANGPTL4 is localized in the
nucleus and is a chromatin-bound protein. This implies that ANGPTL4 could potentially bind to
DNA and affect transcriptional regulation. In addition, the findings of this study showed that
TIP60 and AURKA, predictive interactors of ANGPTL4 are in the nucleus and
compartmentalizes with ANGPTL4. This suggests that their association with ANGPTL4 could
drive tumor progression and metastases. A mammosphere assay was performed to evaluate the
“stemness” capability of TNBC cells expressing ANGPTL4. The results of the mammosphere
assay promote the expansion of the cell colonies in the ANGPTL4 mGFP overexpression in the
TNBC cell line. This indicates that the ANGPTL4 mGFP expressing cell line have stem-cell like

renewal potential in vitro. In this study, the soft agar colony formation assay was performed to
measure the prospective tumorigenic ability of the ANGPTL4 mGFP cell line. The ANGPTL4
mGFP cell line exhibited enhanced anchorage-independence which speaks to the possible
tumorigenic capacity of the cells to be used in in vivo studies.
Subsequently, a mouse model was used to evaluate the metastatic ability of ANGPTL4
primed TNBC cells in vivo. The findings show that MDA-MB-231 ANGPTL4 mGFP cell line
had bigger primary tumors compared to the mGFP cell line expressing endogenous ANGPTL4.
Furthermore, ANGPTL4 mGFP cell line resulted in more metastatic lesions on the liver
compared to the MDA-MB-231 mGFP cell line. Collectively, these findings imply that
ANGPTL4 is a driver of TNBC proliferation and metastases and therefore could be used as a
therapeutic target for TNBC treatment.
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I. INTRODUCTION
I.1 The Molecular Subtypes of Breast Cancer
Breast cancer is the world’s most diagnosed disease ( (Breast cancer now most common
form of cancer: WHO taking action, 2021) and, because of its heterogeneous nature, evidence
suggests that with different histopathological and biological features there are distinct behaviors
that lead to different treatment responses. Due to these responses, specific therapeutic approaches
should be given for breast cancer treatment ( (Blows, et al., 2010).Thus, the accurate grouping of
breast cancers into clinically relevant subtypes is the first important step for therapeutic decisionmaking ( (Dai, et al., 2015).
Consequently, there are five major subtypes of breast cancer ( (Molecular Subtypes of
Breast Cancer, 2021) determined by the presence or absence of the hormone receptor (HR) and
the human epidermal growth factor receptor (HER2/neu). The hormone receptor can be an
estrogen receptor or a progesterone receptor. HR+ (positive) means that tumor cells have
receptors for the hormone estrogen or progesterone that promote the growth of HR+ tumors,
whereas HER2+ means that tumor cells produce high levels of a protein called HER2/neu, which
has been associated with aggressive types of breast cancer. In addition, high or low levels of the
nuclear protein Ki-67 is used to detect how quick cells grow (Li, Jiang, Chen, & Zheng, 2015),
(Sun & Kaufman, 2018).
The first subtype of breast cancer is luminal A, and it has the tendency to progress slowly
and, as a result, has the best prognosis. This type of breast cancer is HR+, HER2 – (negative),
and has low levels of the protein Ki-67. Second, luminal B breast cancer is considered HR+, and
either HER2+ or HER2- with high levels of Ki-67 (National Institute of Health. Surveillance,
Epidemiology, and End Results Program , 2017). Aggressive basal-like, triple-negative breast
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cancer (TNBC) is HR- and HER2- (Keam, et al., 2011), (National Institute of Health.
Surveillance, Epidemiology, and End Results Program , 2017), (Soliman, Khalil, & Antonia,
2014). In addition, HER2-enriched breast cancer is hormone-receptor negative and HER2+, and
they tend to grow faster than luminal cancers and have a potentially worse prognosis, (National
Institute of Health. Surveillance, Epidemiology, and End Results Program , 2017), (Soliman,
Khalil, & Antonia, 2014). However, they are usually successfully treated with targeted therapies
aimed at the HER2 protein, such as Herceptin. Furthermore, normal-like breast cancer is similar
to luminal A disease. However, its prognosis is slightly worse than luminal A cancer’s prognosis
(Herr, et al., 2019)

Table 1.1 - Summary showing the characterizations of the breast cancer subtypes and the
percent survival of each one.
Breast
Estrogen
Progesterone
Human
Ki-67
5-year
Cancer
(ER)
(PR)
Epidermal
Levels
survival
Subtype
Growth Factor
Percentage
Receptor
(%)
(HER2)
Luminal A
+
+
Low
94.3
Luminal B

+

+

+/-

High

90.5

TNBC

-

-

-

High

76.9

HER2-

-

-

+

High

84.0

+

+

-

Low

91.0

enriched
Normal-like

I.2 Triple Negative Breast Cancer Overview
TNBC is defined by the absence of an estrogen receptor, progesterone receptor, and human
epidermal growth factor receptor 2. It is estimated that out of the worldwide breast cancer
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burden, approximately 170,000 cases are TNBC and account for 10-20% of invasive breast
cancers ( (Boyle, 2012), (Foulkes, Smith, & Reis-Filho, 2010), (Kumar & Aggarwal, 2016).
TNBC incidence has been associated with women of color, mutations in breast cancer gene
susceptibility protein 1/2 (BRCA 1/2), women of Jewish ancestry, onset at a younger age,
higher-grade tumors, more advanced tumor grade at diagnosis, and increased recurrence (
(Byrski, et al., 2009) (Comen, et al., 2011), (Dent, et al., 2007), (Foulkes, et al., 2003), (Kirk,
2010) (Lundqvist, Andersson, Ahlberg, Nilbert, & Gerdtham, 2016), (Mavaddat, et al., 2012),
(Musolino, et al., 2007), (Prat & Perou, 2011), (Philipovskiy, Corral, Dwivedi, Heydarian, &
Gaur, 2019), (Turner, Tutt, & Ashworth, 2004).
Epidemiological studies have reported that TNBC is more common in women of African,
Hispanic, and Jewish ancestry ( (Bauer, Brown, Cress, Parise, & Caggiano, 2007), (Carey, et al.,
2006), (Comen, et al., 2011), (Jiagge, et al., 2016), (Kohler, et al., 2015), (Philipovskiy, Corral,
Dwivedi, Heydarian, & Gaur, 2019), (Sørlie, et al., 2001). Additionally, multiple findings have
examined higher prevalence and incident rates, worse clinical outcomes, and mortality rates of
TNBC in African American, Hispanic and Jewish women compared to TNBC in European
American women (Bonotto, et al., 2014), (Clark, Rodriguez, Snyder, Hankins, & Boehning,
2012), (DeSantis, et al., 2019), (Hunter, 2000), (Siegel, Miller, & Jemal, 2016).
The frequency of TNBC in women of color with low survival could be accounted for by
genetic risk and socioeconomic factors. Although (Stewart, et al., 2019) reported that AfricanAmerican women with TNBC showed enhanced BRCA1 gene, BRCA1 is a lower pathogenic
variant compared to the increased BRCA1 mutation incidences in European American women
(Nanda, et al., 2005), (Qian, et al., 2017), (Stewart, et al., 2019). This is due to the abundance of
sequence variations associated with the BRCA1 gene in African-American women which
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inhibits BRCA1 function at a lower rate than in European women (Szabo & King, 1997). In
addition, (Santonja, et al., 2018) reported that Hispanic women with breast cancer have the
highest incidence of pathogenic BRCA1 mutations and this genetic factor may heavily contribute
to the high mortality rates of women with TNBC. (Kwon, et al., 2010) found that more than half
of the Jewish women in their study with TNBC carried a BRCA founder mutation. As a result,
there was a prevalence of BRCA mutations among young and older Jewish women with
TNBC. Furthermore, there was a significant proportion of Jewish women with TNBC and
BRCA2 mutations, meaning that TNBC was not limited to only BRCA1(Comen, et al., 2011).
In addition, numerous socioeconomic factors that influence the access to standard care,
novel treatments, limited healthcare, and inclusion in clinical trials contribute to the overall poor
prognosis of African American and Hispanic women diagnosed with TNBC (Hossain, et al.,
2019), (Lara-Medina, 2011), (Patel, et al., 2010), (Siddharth & Sharma, 2018), (Sturtz, Melley,
Mamula, Shriver, & Ellsworth, 2014), (Elrafei, et al., 2014). Many women of color with breast
cancer have subpar access to appropriate treatment; as a result, there is delayed diagnosis and a
greater tumor burden. The delay in diagnosis could be because of little or no hospitals near the
locations where these women reside, the inability to seek a leave of absence from work due to a
lack of affordability, and no or little access to health insurance (Hossain, et al., 2019), (Parise &
Caggiano, 2018). Latina women are more likely to be uninsured, have lower educational
accomplishments, and have higher poverty rates than European American women (Chlebowski,
et al., 2005). Language, cultural, and financial barriers also play a significant contribution to a
higher mortality rate of TNBC in Hispanic Women (Mack, Pavao, Tabnak, Knutson, &
Kimerling, 2009). Thus, the inaccessibility to health care leads to limited access to standard care
and timely treatment and as result poor overall survival. Moreover, women of color with breast
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cancer generally have a lower participation in clinical trials than their white counterparts, due to
the poor communication and language barriers regarding these trials and their lack of confidence
and trust in medical research. This could be because of the poor care in previous clinical
experiments; for example, the treatment of African-American men in the infamous Tuskegee
Syphilis Study and the study of genetic etiology of aggressive behavior in African-American
boys (Alsan & Graziani, 2019), (Scharff, et al., 2010), (Shavers & Brown, 2002), (US Preventive
Services Task Force, et al., 2019).
TNBC has a more aggressive clinical route with an early age of presentation compared to
the other breast cancer subtypes. The mean age at diagnosis is significantly younger for the
TNBC group at 53.0 years compared with other groups at 57.7 years (Dent, et al., 2007).
Similarly, patients in the TNBC group had a 2-fold increase in grade III tumors compared to the
other breast cancer subtypes, and the mean tumor size was larger in the triple-negative group
than in any group (Dent, et al., 2007). (Collett, et al., 2005) evaluated cancers diagnosed in a
screening program between 1996 and 2001 and found that TNBC was more likely than other
breast cancers to present in the interval between regular mammograms. Also, (Brown, et al.,
2008) reported that TNBC tumors were significantly larger, and they were more likely to present
as stage II or III of the disease.
Most TNBCs are high grade invasive ductal carcinomas (IDCs) with characteristics such
as apocrine differentiation, breast cancer with medullary features, and metaplastic breast
carcinomas (MBCs) (Foulkes, et al., 2010). TNBCs with apocrine differentiation demonstrate the
same growth pattern as IDC, differing only in their cytological appearance. The cells are
characterized by abundant eosinophilic granular cytoplasm (Type A) and multiple nucleoli
(Vranic, et al., 2010), (Yerushalmi, Hayes, & Gelmon, 2009). Thus, these apocrine cells can
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proliferate into atypical lesions. TNBC with medullary features display clearly defined oval
borders, a syncytial growth pattern, and lymphocytic infiltration with high mitotic activity
(Kleer, 2009) (Lakhani, Ellis, Schnitt, Tan, & van de Vijver, 2012) (Pedersen, Schiødt, Holck, &
& Zedeler, 1990). Lastly, MBCs encompass a range of tumors with squamous or mesenchymal
differentiation (Weigelt, et al., 2008). These tumors are most often high grade, with easily visible
abnormal nuclear size and shape with increased mitotic activity. TNBCs with MBCs are resistant
to chemotherapy and have a worse outcome compared to the other subtypes (Jung, et al., 2015)
TNBC is known to have frequent recurrence after diagnosis and more aggressive visceral
metastases which are more likely to occur in the lungs, brain, liver and less likely to spread to the
bone (Criscitiello, Azim, Jr, Linn, & Sotiriou, 2012), (Smid, et al., 2008). A Canadian series
reported by (Dent, et al., 2007) evaluated over 1,500 women diagnosed with TNBC which
showed a higher proportion of local and distal recurrence and death compared to non-TNBC
patients.

Chapter I.3 Triple Negative Breast Cancer Therapeutic Treatment Options
Patients with TNBC derive no advantages from molecularly targeted treatments, such as
endocrine therapy and Herceptin, because they lack the proper targets for these drugs. The
standard approach to treat TNBC has been to use cytotoxic therapeutics, but the chemotherapies
lack the desired selectivity and chemoresistance is a significant problem, demonstrating 90% of
drug failures in metastatic cancers (Longley & Johnston, 2005). Initially, TNBC patients respond
well to neoadjuvant treatments. Unfortunately, there is a possibility of relapse in patients in the
first 5 years in comparison with other breast cancer subtypes (Cinkaya, Akin, & Sengul, 2016).
Nevertheless, neoadjuvant chemotherapy remains the standard care for TNBC patients (Rouzier,
et al., 2005). Currently, neoadjuvant anthracycline–cyclophosphamide (AC-scheme)
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chemotherapy treatment appears to be more efficient, although there have been reports on
resistance developed for these drugs (Geisler, et al., 2001).
In addition, use of anthracyclines (A), taxanes (T), or platinum compounds are also
utilized as adjuvant therapy which works to disrupt cancer cell survival (Liedtke, Mazouni, Hess,
André, & Pusztai, 2008), (Petrelli, De Stefani, Raspagliesi, Lorusso, & Barni, 2014), (Silver, et
al., 2010). (Jones, et al., 2009) published that four-cycle regimens of docetaxel and
cyclophosphamide are more effective than four-cycle regimens of anthracycline and
cyclophosphamide which resulted in longer overall survival of TNBC patients. As a result, the
use of non-anthracycline taxane-containing regimens has become more common. Adjuvant
chemotherapy reduces the risk of recurrence, particularly in patients with tumors greater than one
centimeter. However, A+T treatment increases the risk of cardiac toxicity in older patients
(Schreiber, et al., 2020).
Breast-conserving surgery has been studied as a therapeutic approach to treat TNBC.
(Frasci, et al., 2009) evaluated tests to determine the prognostic effects of mastectomy over
lumpectomy. In TNBC the sole choice of the surgical approach does not improve the prognosis
or inhibit the local tumor recurrence (Freedman, Anderson, Li, & Nicolaou, 2009). A
lumpectomy followed by radiation therapy (RT) could be an option. However, in TNBC the
benchmark treatment is neoadjuvant therapy, and it is preferred before surgery.
Similar to breast surgery RT is part of the treatment regimen for TNBC, though there are
drawbacks (Dawood, Broglio, Buzdar, Hortobagyi, & Giordano, 2010). TNBC is considered an
aggressive subtype which is susceptible to radiotherapy and evidence points out that TNBC
BRCA1 abnormal expression is highly radiosensitive (Abdulkarim et al., 2011). Although
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radiotherapy after mastectomy can improve the results of TNBC, radioresistance is a major
contributor to radiotherapy failure (He, et al., 2018), (Yin, et al., 2016).
Additionally, the use of small molecules to enhance specific delivery and action toward
the direct molecular target has been analyzed as a potential treatment option. Aptamers are
molecules made up of nucleotides, generally in a range of 50 deoxyribonucleic acid (DNA) or
ribonucleic acid (RNA) bases, that are evolved to bind to specific molecular targets. Their small
size makes them suitable to reach molecular targets, therapeutic targets, protein complexes, and
cancer cells (Kulbachinskiy, 2007). Aptamers are easy and cheap to produce but their
degradation in the bloodstream is a clear disadvantage.
TNBC has the worst outcome for immune response treatment because of the higher
expression of the metastasis promoting genes as well as the decreased expression of metastasis
inhibiting genes. Consequently, within the TNBC tumor microenvironment, there are latent
lymphocytes and antigen-presenting cells that do not respond correctly to tumor cells. Recently,
strategies have been implemented to “push” these cells from their quiescent state and initiate a
response that slows the progression of the tumor (Li, Qiu, Lu, Jiang, & Wang, 2018), (Ruffell,
Affara, & Coussens, 2012). It is suggested that cytotoxic T-lymphocyte antigen-4 (CTLA-4)
helps in the downregulation of the immune response (Linsley, et al., 1994). So, the current
efforts are directed to activate immune system response by using CTLA-4 inhibitors such as
ipilimumab. The challenge, however, is that CTLA-4 inhibitors aggressively activate T-cells,
generating different systemic adverse effects (Maker, et al., 2005).
DNA damage of the genome occurs because of base changes, replication errors, free
radicals, chemical agents, cancer therapeutics, and UV radiation (Friedberg, et al., 2006), (Ward,
1988). Double-stranded DNA breaks (DSBs) caused by these agents are detrimental to
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eukaryotic cells so, two DNA repair mechanisms are used: nonhomologous end-joining and
homologous recombination (HR). DSBs produced by collapse of the replication fork are
primarily repaired by HR because the broken ends use homologous sequences from sister
chromatids or regions on the chromosomes to prime repair synthesis (Chen, Yang, & Pavletich,
2008) (Rothstein, Michel, & Gangloff, 2000). Thus, HR is a DNA metabolic process that plays a
vital role in preserving the genome and providing critical support for DNA replication and
telomere maintenance (Degrassi, Fiore, & Palitti, 2004), (Shrivastav, De Haro, & Nickoloff,
2008).
Moreover, HR is dependent on functional BRCA1/2 pathways since BRCA maintains
genome stability by regulating HR according to the type of DNA damage (Prakash, Zhang, Feng,
& Jasin, 2015), (Sadeghi, et al., 2020). Germline mutations in either the BRCA1/2 genes are
associated with a high risk of developing TNBC (Ahn, Kim, Kim, & Jeong, 2016), (Chen, et al.,
2018), (Evans, et al., 2011), (Greenup, et al., 2013). When HR is dysfunctional, repair shifts
toward an alternate DNA repair mechanism dependent on a class of enzymes called polyadenosine diphosphate-ribose polymerase (PARP). PARPs are a family of enzymes involved in
cellular processes such as genomic stability, DNA repair, cell cycle progression, and apoptosis
(Schreiber, et al., 1995), (Skidmore, et al., 1979). PARP-1 functions as a DNA-binding protein,
with nuclear localization which associates with DNA strand breaks as part of the base excision
repair process (Helleday, Petermann, Lundin, Hodgson, & Sharma, 2008), (Plummer, et al.,
2008).
As such, there were preclinical studies that justified the use of PARP inhibitors and
highlighted PARP inhibitors as a promising targeted therapy for aggressive TNBC (Mahany, et
al., 2008). The optimal treatment strategy is the combination of PARP inhibition with either
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cytotoxic DNA-damaging chemotherapeutic agents or with molecular targeted agents that also
impair mechanisms of DNA repair since monotherapy with PARP inhibitors is unlikely to induce
cancer cell death in BRCA-proficient tumors (Alli, Sharma, Sunderesakumar, & Ford, 2009),
(Hastak, Alli, & Ford, 2010), (Papadimitriou, Mountzios, & Papadimitriou, 2018).
However, there are several challenges associated with PARP inhibitor TNBC treatment.
These challenges are establishing optimal therapy to couple with PARP, having a defined
treatment when treating aberrant TNBC metastases, effective administration of cytotoxic
therapies, defining the population most likely to respond to PARP inhibition in the TNBC
community, and analyzing candidate biomarkers to predict how patients respond to treatment
(Dent, et al., 2009), (Edwards, et al., 2008) (Gelmon, et al., 2010), (Rodríguez-Pinilla, et al.,
2006). As a result, investigators must further define TNBC patients most likely to respond to
PARP inhibitors since these drugs are transitioning to adjuvant settings and long-term toxicities
to normal tissues have not yet been characterized for prolonged DNA repair suppression.
Trophoblast cell surface antigen 2 (TROP-2) is a glycoprotein which is overexpressed in
human cancers and, has shown to be a promising therapeutic target (Lipinski, Parks, Rouse, &
Herzenberg, 1981). TROP-2 overexpression in metastatic TNBC accelerates the cancer cell cycle
and drives cancer growth. This antibody was first recognized as a marker of trophoblast cells
and, it was developed looking for a marker for non-small-cell lung cancer (De Leij, Helrich,
Stein, & Mattes, 1994), (Stein, Chen, Sharkey, & Goldenberg, 1990), (Stein, Basu, Chen, Shih,
& Goldenberg, 1993). (Bardia, et al., 2021) reported that 88% of TNBC primary and metastatic
tumors show moderate-to-strong expression of TROP-2. Recently, the FDA granted approval of
Trodelvy (sacituzumab govitecan-hziy) a topoisomerase inhibitor conjugate directed to the
TROP-2 receptor. This approval was based on the results of the ASCENT trial which was
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conducted for the treatment of metastatic TNBC patients. This study showed that there was a
significant difference in survival of TNBC patients treated with sacitizumab-14.2 months
compared to chemotherapy treatment-6.9 months (Bardia, et al., 2021).

I.4 The Metastatic Cascade
The dissemination of TNBC cancer cells and metastatic growth to distal organs
represents a significant health problem. The major secondary sites of metastatic TNBC are the
lungs, liver, and brain (Chambers, Groom, & MacDonald, 2002), (Yao, et al., 2019). The
metastatic disease is incurable and is the primary cause of death for the majority of TNBC
patients. Metastatic spread of tumor cells consists of multiple steps, including local tumor cell
invasion, entry into the vasculature, the exit of carcinoma cells from the circulation, formation of
micrometastases followed by colonization at the distal sites. One of the earliest mentions of
metastases postulated by (Paget, 1989) employing his “seed and soil” theory, proposed that
secondary growth of cancer cells (the “seed”) is dependent on the compatibility of the distal
organ (the “soil”). Currently, this theory has been supported as distinct cancer types metastasize
at different and tumor-specific sites (Mack, et al., 2004), (Nguyen, Bos, & Massagué, 2009).

In this process, cancer cells, after leaving the primary tumor, invade other tissues either
by moving collectively as epithelial sheets, detached clusters, or as single cells (Friedl &
Alexander, 2011).Upon genetic or epigenetic alterations, the TNBC cells at the primary tumor
acquire anti-apoptotic properties such as self-renewal, invasion, and migration abilities to distal
organs. Cancer stem cells are known for their self-renewal and chemoresistance capability, and it
has been shown that TNBC is enriched in cancer stem cells (Honeth, et al., 2008), (Li, et al.,
2013). (Ricardo, et al., 2011) analyzed numerous human breast cancers and evaluated that
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TNBCs harbor the highest percentage of CD44+/CD24- cancer stem cells, a feature that
correlates with metastasis and overall poor survival. Additionally, specific growth factors and
cytokines that activate several stemness pathways have been identified as essential drivers of
TNBC proliferation and stemness (Marotta, et al., 2011).

During local invasion, the cancer cells undergo epithelial-to-mesenchymal transition
(EMT). The crucial steps of tumor metastasis are thought to be enabled by EMT (Ballinger,
Kremer, & Miller, 2016), (Griffiths & Olin, 2012). Cells that have undergone EMT lose their
epithelial organization and can become more motile and less invasive to move as single cells in a
mesenchymal fashion (Mani, et al., 2008), (Thiery, 2002). Transcription factors activate EMT to
promote TNBC cell migration and intravasation in the vasculature (Tran, et al., 2014), (Yang, et
al., 2004). EMT is also associated with cancer stem cell properties, and as mentioned, TNBC
expresses high CD44+/CD24− and EMT markers which is associated with poor survival
outcome (Ma, et al., 2014), (Talukdar, et al., 2019), (Wicha, Liu, & Dontu, 2006).

Upon entering the blood vessels, circulating tumor cells express proteins that have prosurvival functions which allow them to attach and infiltrate specific secondary sites. In addition,
the binding of platelets with circulating breast cancer cells are essential for their survival and
evasion of pro-apoptotic signals (Neophytou, Boutsikos, & Papageorgis, 2018). (Wenzel, Zeisig,
& Fichtner, 2010) evaluated that the disruption of platelet-tumor cell interaction inhibited the
development of lung metastasis in TNBC murine model. Disseminated cells that survive proapoptotic signals in their new environment undergo a dormancy period (Giancotti, 2013).

After extravasation and the escape of the TNBC cells from the dormancy period, genetic
modifications occur, and the cancer cells can form micro and macro-metastatic tumors at the
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secondary sites (De Craene & Berx, 2013)In this step, the reversal to mesenchymal-to-epithelial
transition (MET) phenotype have been shown to be important for metastatic colonization
(Gunasinghe, Wells, Thompson, & Hugo, 2010). MET is characterized by epithelial
reorganization and in this process, the mesenchymal cells regain the epithelial cell-to-cell
junctions for colonization at distal sites (Kalluri & Weinberg, 2009), (Thiery, Acloque, Huang, &
Nieto, 2009).

It is important to understand the insights into the aggressiveness of TNBC by verifying
the interactions between TNBC, CSC and EMT phenotypes. Therefore, understanding these
phenotypes may be promising for exploring the development of novel effective treatments
against metastasis of TNBC.

I.5 Triple Negative Breast Cancer Liver Metastasis
Triple Negative Breast Cancer metastases are common in organs such as the liver, brain,
and lungs (Liedtke, Mazouni, Hess, André, & Pusztai, 2008), (Hess, et al., 2006). BCLM are
present in 15% of patients newly diagnosed with metastatic breast cancer and ultimately 50% of
patients with stage four of the disease will develop liver metastases. When BCLM is left
untreated, patient survival time is only 4 to 8 months with a very rare 5-year survival. Therefore,
early prognosis and detection of liver metastasis is necessary to improve the life expectancy of
TNBC patients (Adam, et al., 2006), (Hoe, Royle, & Taylor, 1991), (O'Reilly, Richards, &
Rubens, 1990) (Selzner, Morse, Vredenburgh, Meyers, & Clavien, 2000). Patients with BCLM
exhibit a wide array of symptoms, which may present asymptomatically during a metastatic
screen or may present with upper abdominal fullness, a mass, ascites, jaundice, or weight loss
(O'Reilly, Richards, & Rubens, 1990). Typically, an ultrasound or computed tomography (CT)
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scan confirms the diagnosis. However, there have been two case studies in which asymptomatic
presentation has been shown. Women of Asian and European American descent both conferred
with TNBC via an abdominal CT scan, presented with liver metastases (Chue & La Course,
2019), (Ogata, et al., 2015).

The molecular mechanisms underlying breast cancer metastasis have been especially
reported for the lungs and bone (Chiu, et al., 2013), (Gao, et al., 2012), (Jiang, et al., 2012),
(Minn, et al., 2005), (Suva, Griffin, & Makhoul, 2009), (Zhang, et al., 2013); however, the
molecular mechanisms for BCLM have not been as thoroughly described (Lu, et al., 2007).
(Parks & Garden, 2001) reported that the biological structure of the liver also makes it highly
advantageous. The beneficial features are the abundant blood supply, the fenestrated blood
vessels, and the lack of a sub-endothelial basement membrane. This allows for the movement
and progression of the breast cancer cells within the liver microenvironment (Ma, et al., 2015).

BCLM is associated with a few characteristics that result in the successful colonization of
the secondary organ. These qualities include stem cell properties and proliferation signaling
(Hess, et al., 2006), (Homayounfar, et al., 2013). Also, the breast carcinoma cells that secrete
cytokines, chemokine receptors, cadherins promote cell adhesion to the endothelium, and
integrin complexes which promote breast cancer cells to metastasize to the liver (Ma, et al.,
2015), (Wendel, et al., 2012).

I.6 Triple Negative Breast Cancer Liver Metastasis Therapies
A further understanding of the roles of TNBC cells and the liver microenvironment in
early breast cancer metastasis is crucial for the development of effective BCLM therapies (Paget,
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1989), (Price, Polyzos, Zhang, & Daniels, 1990). Current treatments for TNBC are systemic
chemotherapy and radiation as the first-line treatment for cancer that has metastasized (Davis,
Eckhardt, Tentler, & Diamond, 2014), (Cardoso, et al., 2018), (Hortobagyi, et al., 2005),
(Schmid, et al., 2018), (Senkus, et al., 2015). However, even with these treatments patients
ultimately become resistant to palliative therapy and have a poor response to chemotherapy
which results in increased mortality in BCLM patients (Yao, et al., 2017).
Raised serum alkaline phosphatase (ALP) has been established in patients with metastatic
colorectal cancer but has not yet been evaluated as a diagnostic tool in BCLM. However, there
have been small studies suggesting that elevated ALP, though not specific to liver metastasis is
still useful in aiding the detection of the liver metastatic disease (Kamby, et al., 1987), (Klompje,
Petrelli, Herrera, & Mittelman, 1987), (Warnes, Hine, Kay, & Smith, 1981). (Saif, Alexander, &
Wicox, 2005) reported that patients with increased ALP levels were 5.5 times more likely to
develop liver metastasis that patients with normal ALP levels. Thus, monitoring ALP levels at
each patient’s follow-up can be used as an indicator since having liver metastasis is a good guide
of disease progression. ALP is a simple, cost-conscious, and sensitive screening tool for
detecting liver metastasis and can be developed in future studies of TNBC liver metastasis as a
diagnostic tool.
In several countries, such as Japan and Europe, other approved treatment options such as
combined bevacizumab/paclitaxel/carboplatin (BCP) have been used for BCLM. BCP therapy
has been used in the treatment of non-small cell lung cancers and significant improvements in
survival rates have been reported (Sandler, et al., 2006). Additionally, (Ogata, et al., 2015)
showed the successful treatment of BCP therapy in metastatic TNBC. Most importantly, the
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patient has been in complete remission without additional treatment and has remained diseasefree after 5 years. Thus, this treatment has shown future promise for metastatic TNBC.
Alternatively, (Chue & La Course, 2019) demonstrated the use of metronomic
chemotherapy as a viable TNBC liver metastasis treatment option. Metronomic chemotherapy
uses lower doses of chemotherapy agents with higher dose intensity (the total dose of
chemotherapy administered per unit time) while switching chemotherapy regimens every few
weeks. This prevents the development of disease resistance and a better chance of achieving
long-term survival (Greaves & Maley, 2012). However, drug resistance is still seen as the
primary cause of failure of chemotherapy treatment for metastatic cancer and continuing a
chemotherapy regimen until disease progression will inevitably increase the likelihood of a
chemotherapy-resistant disease.
More accumulated evidence suggested that the metastatic TNBC subtype can be
particularly responsive to immunotherapy (García-Teijido, Cabal, Fernández, & Pérez, 2016).
(Schmid, et al., 2018) study showed that treatment with atezolizumab–nab-paclitaxel benefitted
patients with the programmed cell death-1 (PD-1) signal pathway which has a ligand called PDL1 that leads to apoptosis of malignant cells for TNBC (González-Cao, et al., 2015), (Pardoll,
2012), (Wimberly, et al., 2015). The presence of PD-L1 may be a result of genetic events leading
to constitutive PD-L1 expression on cancer cells versus non-cancer cells in response to a T cell
infiltration. Thus, it is important to determine the PD-L1 expression status on tumor-infiltrating
immune cells since it can be used as a treatment choice for patients with metastatic TNBC.
Currently, Ipilimumab, pembrolizumab (anti-PD-1), and atezolizumab have been approved by
the FDA in patients with overexpression of PD-L1 which helps in the therapeutics of TNBC
patients with metastatic cancer (Narayan, et al., 2020). Furthermore, two new PD-L1 inhibitors
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mepolizumab and nivolumab have been tested in current clinical trials. Unfortunately, 76% of
TNBC patients having PD-L1 expression have not shown therapeutic response under
mepolizumab therapy (Gibson, Delaune, Szady, & Markham, 2016).
TNBC metastatic cancers can escape an antitumor immune response through the
upregulation of regulatory T cells, secretion of immunosuppressive cytokines into the tumor
microenvironment, as well as the expression of immunosuppressive proteins (Bohling & Allison,
2008), (Drake, Jaffee, & Pardoll, 2006), (García-Teijido, Cabal, Fernández, & Pérez, 2016),
(Smyth, Godfrey, & Trapani, 2001). Unfortunately, this situation is further exacerbated by the
immunosuppressive effect of standard-dose chemotherapy (Kang, et al., 2009). Thus, the
recruitment of the regulatory molecules to the tumor site may disarm the T-cell effectors and
therefore favor the immunosuppressive activity of the tumor. As a result, this outweighs the
body's antitumor immune response and consequently promotes tumor progression (Rabinovich,
Gabrilovich, & Sotomayor, 2007).
Moreover, a less arduous and more favorable treatment for TNBM liver metastasis is
percutaneous ablation where doctors can utilize heat or cold to burn or freeze the tumor through
a puncture thereby killing it. Using this method, high doses of ultrasound therapy can be applied
to kill the tumor. Medical doctors also reported the establishment of a regional therapy technique
when the tumors are multiple or diffuse. This therapy is chemoembolization, which means
inserting a catheter that goes directly into the liver’s arteries to deliver very high levels of
specialized toxic drugs precisely to the tumor (Yale Medicine, 2021)
Methionine dependence is linked to epigenetic changes in cancer controlled by
methylation events and is demonstrated as a promising target of metastatic TNBC (Hoffman,
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2015). Cancer cells require increased levels of methionine (MET- dependence) due to the higher
overall rates of transmethylation in comparison to normal cells (Coalson, Mecham, Stern, &
Hoffman, 1982). (Kaiser, 2020) described the necessity of the cancer cells to have high
methionine, is known as the Hoffman effect, analogous to the Warburg effect which describes
the glucose overuse of cancer cells. In current research studies, recombinant methionase (orMETase) inhibited the growth of the metastasis of cancer cells in vitro and in vivo (Hoffman,
2015), (Lim, et al., 2020). These results suggest that o-rMETase has the potential as a new
effective modality for metastatic TNBC, especially since it can be administered orally without
toxicity (Han, Tan, & Hoffman, 2020), (Kawaguchi, et al., 2019).

I.7 Angiopoietin-like protein 4 background and structure
The angiopoietin-like protein 4 (ANGPTL4) was discovered approximately two decades
ago and belongs to the angiopoietins family of secreted proteins which plays a role in the
formation blood vessels. The eight members of angiopoietins are identified in humans and mice,
except ANGPTL5, which is only found in humans (Ito, et al., 2003), (Kim, et al., 2000),
(Santulli, 2014). All angiopoietin-like proteins have a C-terminal fibrinogen-like domain and an
N-terminal coiled-coil domain.
ANGPTL1 to 4 and ANGPTL6 have been shown to regulate angiogenesis. ANGPTL3 to
6 and 8 are involved in the regulation of lipid metabolism, glucose and energy homeostasis
(Koliwad, Gray, & Wang, 2012), (Oike, et al., 2005), (Xu, et al., 2005). (Lee, et al., 2009)
evaluated that ANGPTLs 3 and 4 control lipid metabolism by inhibiting the activity of
lipoprotein lipase, an enzyme that is responsible for the hydrolysis of triglycerides. ANGPTL4 is
primarily present in the liver, adipose tissue, and skeletal muscle (Dijk, et al., 2015), (Kersten, et
al., 2009), (Oike, et al., 2005), (Tan, Teo, Sng, Zhu, & Tan, 2012).
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ANGPTL4 is evolutionarily conserved among species and the sequence is closely
homologous with mice. It is located on chromosome 19p13.3 and comprised of seven exons with
a 406-amino acid glycoprotein. ANGPTL4 contains a hydrophobic region that acts as a signal
peptide for protein secretion and exhibits several N- and O-glycosylation sites (Grootaert, Van de
Wiele, Verstraete, Bracke, & Vanhoecke, 2012). Different studies showed that the nANGPTL4
domain is used to modulate lipid metabolism, whereas the cANGPTL4 domain may be a
modulator of the tumorigenesis process (Tan, Teo, Sng, Zhu, & Tan, 2012). ANGPTL4 functions
as a LPL inhibitor due to an protein synthesis process mediated by the N-terminal region
responsible for its assembly into 3D protein structures. Experimental analyses showed that
proprotein convertases like furin, proprotein convertase 5/6, and proprotein convertase
subtilisin/Kexin type 3 catalyze the proteolytic processing of the human flANGPTL4 protein via
a particular amino acid sequence, which causes the release of the N-terminal region and a Cterminal portion (Lei, et al., 2011), (Yau, et al., 2009). As a result, the shortened form of
ANGPTl4 is secreted from the liver, whereas the full-length form is released from adipose tissue.
Since ANGPTL4 expression was found mainly in the liver and adipose tissue, it was classified as
an adipokine and as such its involvement in lipid metabolism is well characterized.
Subsequently, many studies showed ANGPTL4 plays a highly versatile role in angiogenesis,
vascular permeability, tumorigenesis, lipid metabolism and inflammation.

I.8 The Role of ANGPTL4 in TNBC
I.8.1 ANGPTL4 and regulatory factors in human cancers
Previous studies have demonstrated that ANGPTL4 is involved in cancer growth,
progression, angiogenesis, metabolism, and metastasis (Galaup, et al., 2006), (Kim, et al., 2011),
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(Padua, et al., 2008), (Tan, Teo, Sng, Zhu, & Tan, 2012), (Zhu, et al., 2011). In several cancer
types, the diverse roles of ANGPTL4 remain controversial and have reported involvement with
many different signaling molecules and pathways. Several studies show that high levels of
ANGPTL4 are associated with poor prognosis in patients with various solid tumors. This
suggests that ANGPTL4 gives the cells the ability to acquire sustained proliferation, evading
growth suppressors, resist apoptosis, replicative immortality, angiogenesis, invasion, and
metastasis (Hanahan & Weinberg, 2011).
Several studies have reported that the transcription factor hypoxia-inducible factor-1α
(HIF-1α) stimulated by hypoxia can induce the upregulation of ANGPTL4 which stimulates
angiogenesis (La Paglia, et al., 2017), (Kim, et al., 2011), (Li, et al., 2007), (Zhu, et al.,
2011). Additionally, a previous study demonstrated that ANGPTL4 upregulation in endothelial
cells plays a key role in the tumorigenesis of Kaposi’s sarcoma (Hu, et al., 2016). Furthermore,
evidence suggests that ANGPTL4 acts via the transforming growth factor β (TGF-β) signaling
pathway to promote tumor invasion and metastasis (Mathieu, et al., 2014). Moreover, ANGPTL4
is the potential target gene for the three isoforms of peroxisome proliferator-activated receptor
(PPAR) and PPARs have been implicated in the development of tumors in breast cancer cell
lines (Girroir, et al., 2008), (Kim, et al., 2011). For other human cancers, studies reported that
ANGPTL4 promotes invasion and metastasis as well (Dong, et al., 2017), (Hu, et al., 2016),
(Nakayama, et al., 2011).
These findings implicate ANGPTL4 in cancer progression, invasion, angiogenesis, and
metastasis. More importantly, the research suggests that the expression and the role of
ANGPTL4 in tumors are dependent on context and tumor type. This suggests the clinical
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importance of ANGPTL4 in tumor biology and the research necessary to evaluate an effective
targeted therapy against it.

1.8.2 ANGPTL4 Primes Tumor Progression
Increased ANGPTL4 expression has been shown to contribute enhanced tumor
progression, metastasis, and poor overall survival. Conversely, studies have reported that the
inhibition of ANGPTL4 reduces metastasis and tumorigenesis (Dao, et al., 2020), (Gong, et al.,
2019), (Kim, et al., 2011), (Padua, et al., 2008), (Zhao, et al., 2020), (Zhu, et al., 2011), (Wang,
et al., 2013). As such it important to understand the role ANGPTL4 plays as a driver in tumor
progression.

In the (Gong, et al., 2019) study, the researchers evaluated the role of ANGPTL4 as
promoter for TNBC brain metastasis in vivo and to further understand the interaction of the
cancer cells with the astrocytes comprising of the human blood brain barrier in vitro. (Wang, et
al., 2013) published that TNBC cells passaged in astrocyte cell medium enhanced brain trophism
in a murine model. These observations suggested that the medium derived paracrine signaling of
growth factors to promote seeding and metastasis of the brain. Thus, (Gong, et al., 2019)
evaluated the role of ANGPTL4 expression in TNBC cells in astrocyte medium and found that it
was induced by TGF-B and ANGPTL4 was significantly elevated suggesting their roles in tumor
progression and metastasis. In the murine model, ANGPTL4 shRNA was expressed in the MDAMB-231 cell line and reduced the ability of the cancer cells to progress, seed and colonize the
brain. As such (Gong, et al., 2019) reported ANGPTL4’s contribution to the metastatic lesions of
MDA-MB-231 cells in the brain.

21

In another study, (Padua, et al., 2008) evaluated ANGPTL4’s function in TNBC
colonization of the lung. The lung is one of the more common sites that TNBC cells can seed and
metastasize. To investigate whether ANGPTL4 is involved in the metastatic colonization of the
lungs, this research group inhibited the expression of ANGPTL4 in a TNBC cell line and
orthotopically injected the TNBC cells in a murine model. They reported that the seeding to the
lungs decreased more than 10-fold, suggesting that ANGPTL4 is involved in cancer cell’s ability
to survive in circulation and seed to the lungs. In addition, they showed that the overexpression
of ANGPTL4 in TNBC cells increased lung colonization by these cells. These results provide
evidence that ANGPTL4 expression is necessary for the ability of TGFβ to prime the breast
cancer cells for invasion of the lungs.

Furthermore, (Padua, et al., 2008) investigated whether ANGPTL4 can affect the
extravasation of the breast cancer cells through the endothelial tight junctions of the lung
parenchyma. A lung permeability assay was performed in vivo with rhodamine signal. The
TNBC cells expressing ANGPTL4 showed a 3-fold increase in the rhodamine signal, showing
that ANGPTL4 can disrupt the integrity of the endothelial cell tight junctions and aid in
colonization of the lungs. To further understand the role of ANGPTL4 in the TNBC migration
through the cell-to-cell endothelial junctions an assay using tissue culture inserts. It was shown
that TNBC cells overexpressing ANGPTL4 passed twice as much through the endothelial layers
compared to control cells. This demonstrates that Angptl4 disrupts the integrity of vascular
endothelial cell layers both in vitro and in the lungs, facilitating the passage of breast cancer cells
(Bos, et al., 2009). Jointly, (Padua, et al., 2008) showed that of ANGPTL4 enhances TNBC cells
migration, tumor progression, and extravasation to the lungs.
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(Dao, et al., 2020) investigated the role of ANGPTL4 fragments in brain metastasis using
a murine model. This group found that ANGPTL4 concentration in the serum is directly
proportional to the increased risk of brain metastases and shorter survival in patients with breast
cancer. Multivariate analyses performed by this research group showed that metastases were
significantly associated with elevated ANGPTL4 concentration in the serum. In addition, they
evaluated the proliferative, invasive, and migratory abilities of the breast cancer cells expressing
nANGPTL4 and cANGPTL4 fragments. It was reported that tumor cells expressing the different
fragments of ANGPTL4 had increased proliferation, migration and invasion compared to the
wild type cells. For in vivo experiments, mice injected with cells expressing the fragment of
nANGPTL4 had a shorter median survival of 19 days compared median time of 23 days for mice
injected with wild-type cells. In addition, the mice injected with ANGPTL4 expressing cancer
cells had significantly larger lung and brain metastasis compared to the mice injected with
wildtype cells.

(Zhao, et al., 2020) reported the association between ANGPTL4 expression and the
different breast cancer tissues. They evaluated the expression levels of ANGPTL4 in different
breast cancer tissue and shown that 63% of ANGPTL4 is expressed in IDCs, the highest
percentage of ANGPTL4 expressed among all the breast cancer tissues. This means that as the
malignancy of the tissues increased the rate of ANGPTL4 expression increased. Consequently,
ANGPTL4 expression was associated with the worst prognosis in patients with IDC.
Collectively, the in vivo and in vitro models in these studies of breast cancer have
demonstrated the ability of ANGPTL4 to enhance tumor proliferation, migration, disruption of
the endothelium cell-to-cell junction, invasion, and metastasis.
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1.8.3 ANGPTL4’s Role in Anoikis Resistance
Tumor cells abnormal growth suggests that anoikis should follow due to the stresses the
cells are experiencing and, as a result cell growth progression should halt. However,
proliferation, cell migration and metastasis continue to occur. This suggests that the cells are no
longer reliant on the extracellular matrix for attachment and that the tumor cells have undergone
anoikis resistance. Anoikis resistance is defined as the cells ability to evade cell death when there
is loss of attachment to the extracellular matrix.
(Zhu, et al., 2011) reported that enhanced ANGPTL4 expression promotes anoikis
resistance to tumors via autocrine adhesion mimicry. It is noted that cANGPTL4 was detected
and elevated in many human tumor cells (Hanahan & Weinberg, 2011).
In their study, suppression of ANGPTL4 in the cancer cells formed 85% less colonies on
a soft agar colony formation assay compared to the control cell line. In addition, in the anoikis
assay the ANGPTL4 shRNA cell line was more susceptible to anoikis and resulted in 30% more
apoptotic cells than the control cell line.
The anoikis resistance effect of ANGPTL4 is mediated by reactive oxygen species
(ROS). ANGPTL4 activates ROS which leads to an anti-apoptotic and anchorage-independent
signals resulting in the tumor cells not being reliant on the extracellular matrix for normal
growth. cANGPTL4 specifically binds to integrins βeta-1 and βeta-5 on tumor cells and activates
pro-survival pathways, which further stimulates NADPH oxidase 1 activation via autocrine
signaling (Zhu, et al., 2011). However, paracrine signaling can occur if the tissue expressing
elevated cANGPTL4 is near the tumor (Desgrosellier & Cheresh, 2010). Downstream, this
further triggers the inhibition of apoptotic proteins resulting in resistance to anoikis and favoring
tumor survival and growth.
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In a separate study, (Liao, et al., 2017) evaluate EGF-induced ANGPTL4 in tumour cells
and anoikis resistance capability. The study showed that the secretion of EGF-induced
ANGPTL4 was inhibited in ANGPTL4 shRNA cells which resulted in the reduction of EGFinduced anoikis resistance. Conversely, the reduction of anoikis resistance could be reversed by
treating the ANGPTL4 shRNA cells with recombinant cANGPTL4. Consequently, they
evaluated that EGF-induced ANGPTL4 by autocrine signaling significantly enhanced anoikis
resistance. Moreover, (Terada & Nwariaku, 2011) demonstrated that tumour derived ANGPTL4
increases the production of ROS, resulting in activation of survival pathways to enhance anoikis
resistance.
1.8.4 ANGPTL4’s Role in Hypoxia and Angiogenesis
Hypoxia induced by the overconsumption of oxygen by the rapidly growing tumor cells
results in an oxygen deficit. This hypoxic environment triggers the onset of angiogenesis, which
forms new blood vessels to supply oxygen, nutrients and remove metabolic waste products
supporting tumor survival (Bertout, Patel, & Simon, 2008). It has been examined that
angiogenesis is a multistep process that is regulated by vascular endothelial growth factors and
ANGPTL4 (Le Jan, et al., 2003). Studies highlighted a prominent role for ANGPTL4 in tumor
angiogenesis and vascular permeability. This increase in ANGPTL4 expression enhanced
endothelial cell migration and differentiation, both of which are important processes in
angiogenesis, resulting in increased neovascularization (Padua, et al., 2008).
(Zhang, et al., 2012) identified that ANGPTL4 is a hypoxia-inducible factor 1 (HIF-1)
target that contributes to vascular metastasis. HIF-1 is characterized as a transcription factor that
occurs because of reduced oxygen availability and regulation of the genes that play roles in many
factors of molecular biology like angiogenesis (Semenza, 2010).
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(Le Jan, et al., 2003) indicated both the mRNA and protein ANGPTL4 levels become
elevated because of hypoxia and, as a result exerts a proangiogenic effect. An elevated
expression of ANGPTL4 was observed in breast cancer with the expression of cANGPTL4
fragment highly correlated to the expression of HIF-1α (Zhang, et al., 2012). These observations
indicate that ANGPTL4 could be a key modulator in tumor angiogenesis in a hypoxic tumor
microenvironment.
HIF-1 targets include numerous genes that play essential roles in promoting angiogenesis
to increase oxygen delivery. Consequently, tumor cells metabolically shift from oxidative
phosphorylation to glycolysis and lactic acid production to decrease oxygen demand. Thus,
protecting cells from acidosis and influencing adaptive survival mechanisms (Semenza G. L.,
2012). Hypoxia is one of the most common and important factors identified in the regulation of
cancer progression and metastasis (Kaelin, 2005), (Semenza G. L., 2012).

I.9 TNBC and Tat-interactive protein p60
Tat-interactive protein p60 (Tip60) is a member of the histone acetyltransferases and is
directly involved in genome maintenance, gene regulation, and DNA damage repair pathways.
Tip60 is the acetyltransferase component of a multiprotein complex that includes 16 subunits and
contains an ATPase, p400 which can sensitize cells to death, and helicases-Tip49a and Tip49b
(Fuchs, et al., 2001), (Samuelson, et al., 2005). The Tip60 complex preferentially acetylates
histone binding acetylation targets H2AK5, H3K14, and H4K5/8/12/16 (Kimura & Horikoshi,
1998). As a result of DNA damage, Tip60 is induced and then acetylates kinase activity at the
sites of the damage (Legube, et al., 2002), (Sun, Jiang, & Price, 2010). Moreover, (Halkidou, et
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al., 2003) reported that Tip60 predominantly accumulates in the nucleus of the tumor cell than a
more diffused pattern which was observed in a benign state of prostate cancer.
Tip60 roles are not only limited to DNA repair but also in apoptosis. Researchers have
evaluated the relationship between Tip60 and cancer, which showed that Tip60 functions as a
tumor suppressor (Gorrini, et al., 2007), (Squatrito, Gorrini, & Amati, 2006). In human cancers,
Tip60 mRNA or protein level was downregulated and associated with poor prognosis in these
patients (Chevillard-Briet, et al., 2014), (Gorrini, et al., 2007), (Mattera, et al., 2009), (Zhao, Jin,
& Gewirtz, 2012). It is also reported that in TNBC there are low expressions of TIP60 protein
and RNA compared with luminal subtypes. (Idrissou, et al., 2020) reported successful inhibition
of TIP60 activity in a TNBC cell line with chemical inhibitors. Studies on histone modifications
in the appearance and progression mechanisms in TNBC would be essential in understanding the
performances of TIP60 tumor biology (Stacy, et al., 2019).
Although the effect of histone alterations has not been fully understood, histone modification
inhibitors such as histone deacetylase inhibitors have emerged as a promising class of
multifunctional anticancer agents to potentially prevent TNBC growth and metastasis (Fedele,
Orlando, & Cinieri, 2017). These inhibitors could also help to better understand the effect of
histone modifications on the outcome and the metastasis of TNBC through gene expression
regulation to define new biomarkers and targeted therapies (Fedele, Orlando, & Cinieri, 2017),
(Tate, et al., 2012). Tip60 was chosen for this study because it is suggested to be an interactor or
in the pathway with ANGPTL4 as such it would be interesting to identify and understand its role
in TNBC overexpressing ANGPTL4 cells. Studying this protein could potentially be used to
further understand if ANGPTL4 and TIP60 are working together to affect the tumorigenic ability
of the TNBC cells.
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I.10 TNBC and Aurora Kinase A
Abnormalities in genes controlling the cell cycle causes atypical cell proliferation,
apoptosis, and transformation of malignant cells (Golias, Charalabopoulos, & Charalabopoulos,
2004), (Williams & Stoeber, 2012). Aurora kinases (AURKA) are a family of mitotic
serine/threonine kinases involved in different processes of cell cycle regulation and are
associated with several co-activators that drive localization and activation during cell division
(Barr & Gergely, 2007), (Fu, Bian, Jiang, & Zhang, 2007), (Vader & Lens, 2008). AURKA is
overexpressed in many types of human cancers, notably in the different subtypes of breast
cancers (Dar, Belkhiri, & El-Rifai, 2009), (Sen, et al., 2002), (Tanaka, et al., 1999). This
overexpression correlates with tumorigenesis and metastasis confirming the survival function of
AURKA in cancer cells. AURKA overexpression may occur by gene amplification, transcription
activation, or suppression of protein degradation. Multiple studies evaluated different cancers
and, showed that AURKA transcription may be induced by HIF-1α (Klein, Flügel, & Kietzmann,
2008), (Lehman, et al., 2012).

However, the molecular and transcriptional regulation mechanisms of AURKA remain
unknown, especially in TNBC. (Fanale, et al., 2013) reported that hypoxia directly links HIF-1
with AURKA expression in hormone-positive and HER2 overexpressing breast cancer cell lines
and to a lesser extent TNBC. This highlights a possible pathophysiological role of this pathway
in tumors and confirms that HIF-1 has an important role in signaling to the AURKA promoter.
Since AURKA is a key regulator of the chromosomal segregation process in mammalian cells
these results could provide innovative approaches for the development of possible therapeutic
strategies against TNBC (Lee, et al., 2019). AURKA was chosen for this study because it is
suggested to be an interactor with TIP60 or in the pathway with ANGPTL4. Therefore, it would
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be noteworthy to identify its role in TNBC overexpressing ANGPTL4 cells. Studying this
protein could potentially be used to further understand if its interaction with TIP60 and
ANGPTL4 would be a driver for the tumor progression of the TNBC cells.

1.11 Controversial Role of ANGPTL4 in Cancer
ANGPTL4’s function remains debatable because of its multifaceted roles and, therefore
further clarification is needed in tumorigenesis. However, several research groups have shown
promising results suggesting that ANGPTL4 could be a potential therapeutic target in the battle
against TNBC (Huang, et al., 2011), (Kim, et al., 2011), (Padua, et al., 2008), (Zhu, et al., 2011).
It was reported that the immunosuppression of cANGPTL4 by neutralizing antibodies results in
tumor regression, reduced vascular disruption, and metastasis (Huang, et al., 2011), (Zhu, et al.,
2011). Moreover, the inhibition of cANGPTL4 could potentially aid in chemosensitivity to
cancer cells (Kim, et al., 2011). Given the implications that ANGPTL4 may have on cancer
progression, a report suggested that ANGPTL4 mRNA could be used as a diagnostic marker to
distinguish primary and metastatic cells in renal carcinoma (Verine, et al., 2010). A few other
studies have also described ANGPTL4 expression level in primary and invasive tumors, that
showed high ANGPTL4 mRNA and protein expression in human tumor biopsies often correlated
with a poor prognosis and disease outcome (Hu, et al., 2016), (Kim, et al., 2011). (Zhu, et al.,
2011) and colleagues have shown that increased cANGPTL4 protein levels could be detected in
the serum of tumor-bearing mice. cANGPTL4 was also found to be secreted by hypoxic cancer
cells, lending further confidence to the potential use of ANGPTL4 as a biomarker (Kim, et al.,
2011).
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Conversely, multiple studies reported that enhanced ANGPTL4 expression has inhibited
tumor progression, invasion, and metastasis of tumor cells (Cazes, et al., 2006), (Galaup, et al.,
2006), (Ito, et al., 2003), (Le Jan, et al., 2003). Consequently, ANGPTL4 has been reported in
promoting cancer cell’s tumorigenesis while also inhibiting tumor progression in different
cancers (Ito, et al., 2003), (Le Jan, et al., 2003), (Ma, et al., 2015). Thus, ANGPTL4’s role in
cancer progression needs to be further understood and more importantly its role in TNBC.

1.12 Research Aims
ANGPTL4 was shown to drive the invasion and metastatic capability of TNBC across the lung
and brain parenchyma, this led to the central hypothesis that ANGPTL4 primes TNBC cells to
disseminate and metastasize to the liver. ANGPTL4 is known as a secreted protein in the plasma
membrane and serves a multifaceted role in cancer progression. Thus, the first aim of this study
is to evaluate the role of intracellular ANGPTL4 in TNBC cells. Also, to investigate the
localization and interaction of TIP60 and AURKA with ANGPTL4 experimentally. Since, TIP60
and AURKA are predicted to be interactors in the ANGPTL4 pathway. The second aim is to
assess the tumorigenic ability of exogenous ANGPTL4 in TNBC cells using a murine model.
Research aim 1: The first aim was to assess the mechanism of intracellular ANGPTL4 in
TNBC cells and examine the localization and compartmentalization of TIP60 and AURKA in the
ANGPTL4 pathway in vitro.
Research aim 2: The second aim was to evaluate the role of tumor-derived ANGPTL4
overexpression in TNBC cells as a driver of metastases in vivo.
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II. CHARACTERIZATION OF ANGPTL4 OVEREXPRESSION IN TNBC IN VITRO
II.1 Introduction
In this study the role of intracellular ANGPTL4 in TNBC cells and its ability to drive
proliferation was evaluated. ANGPTL4 has been established as an enhancer of tumor
progression in TNBC and a driver of lung, liver, and brain metastasis. Studies have reported that
intracellular ANGPTL4 primes TNBC to extravasate and colonize the lung and brain
parenchyma via TGF-B pathway (Gong, et al., 2019), (Padua, et al., 2008). In addition,
ANGPTL4 promotes TNBC cells to escape anoikis. The breast cancer cells can grow in the
absence of EMT attachment and with signaling from pro-survival proteins they gain anchorage
independence where the cells continue to grow, migrate, and survive in the vasculature (Zhu, et
al., 2011). In addition, TNBC is known to be enriched for stem cells, the CD44 high and CD24
low phenotype, this means that the cancer stem cells have self-renewal, aggressive and increased
metastatic ability (Idowu, et al., 2012), (Ricardo, et al., 2011). A study also reported that
ANGPTL4 suppression inhibited the proliferation and migration of cancer cells in vitro,
therefore solidifying its important in cancer progression (Huang, et al., 2011). Collectively, these
studies indicate ANGPTL4 as a driver of metastatsis by enhancing tumor growth, cell motility
and invasion (Tan, Teo, Sng, Zhu, & Tan, 2012).
In this study, a lentiviral transduction was performed to overexpress ANGPTL4 in TNBC
cell line and the overexpression was confirmed using confocal microscopy, ELISA and
immunoblot analysis. The Human Protein Atlas predicted that ANGPTL4 is in the nucleoplasm
and possibly in the vesicles, however the nuclear and chromatin localization of ANGPTL4 in
TNBC has not been shown. In addition, TIP60 and AURKA are suggested to be interactors in the
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ANGPTL4 pathway, as such ANGPTL4, TIP60 and AURKA localization were evaluated using
immunofluorescence microscopy and western blot analysis.

TNBC has the highest percentage of cancer stem cell population and is predicted to be
more invasive and metastatic that the other breast cancer subtypes. To evaluate the ability of
TNBC ANGPTL4 cells to form mammospheres and their ability to have an enriched stem cell
population. A mammosphere assay was done with immunoblot analysis to confirm the stem cell
phenotype by using CD44 and CD24 markers.

In this study, Oil Red O staining was performed to evaluate the lipogenic profile of the
TNBC cell line that overexpressing ANGPTL4 mammospheres. Furthermore, soft agar colony
formation assay was done to assess anchorage independence in addition to cell colony growth
and size in the TNBC ANGPTL4 cell line.
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II.2 MATERIALS AND METHODS
II.2.1 Cell Culture
MD Anderson metastatic breast cancer 231 cells (MDA-MB-231), a TNBC cell line was
cultured in Delbucco’s Modified Eagle Medium Nutrient Mixture F-12 (DMEM/F12 HAM)
containing 5% fetal bovine serum (FBS), and 10 μg/ml gentamicin (complete medium) under 5%
CO2 at 37°C. The MDA-MB-231 cells that overexpress mGFP tagged ANGPTL4 and mGFP
only were cultured in Delbucco’s Modified Eagle Medium Nutrient Mixture F-12 (HAM)
containing 5% FBS, 10 μg/ml gentamicin and 2 μg/ml puromycin at 37 °C under 5% CO2.

II.2.2 Lentiviral mediated ANGPTL4 overexpression
The MDA-MB-231 cell line was purchased from Sigma-Aldrich and, the lentiviral
particles for the transduction was obtained from Origene. 1x105 MDA-MB-231 were seeded in a
24 well plate and incubated for 24 hours. Then, the cells were transduced with the respective
plasmids for 16 hours with 8 ug/ml of polybrene. Then, the virus-containing medium was
removed and replaced with fresh complete medium. Selection with puromycin at 2 μg/ml was
initiated 24 hours after transduction and continued for two weeks. Single cells were propagated
for three weeks. Colonies with robust GFP expression was determined by fluorescence
microscopy and fluorescence activated cell sorting (FACS) were used in all subsequent
experiments.

II.2.3 Subcellular Protein Extraction
Using MDA-MB-231 mGFP and MDA-MB-231 ANGPTL4 mGFP cell lines, they were
lysed, and cell fractions were isolated. This was done using a Subcellular Protein Fractionation
kit (Thermo Fisher Scientific) for cultured cells according to the manufacturer’s guidelines.
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II.2.4 Western Blotting
ANGPTL4 overexpression in the MDA-MB-231 cell line was confirmed with SDS-Page
and immunoblot analysis with an ANGPTL4 antibody(). MDA-MB-231 mGFP and ANGPTL4
mGFP cells were rinsed twice with ice-cold PBS and attached cells were lysed in ice-cold Pierce
Immunoprecipitation buffer containing Halt™ protease and phosphatase inhibitor cocktail
(Thermo Fisher Scientific) according to the manufacturer’s instructions. The lysates were
transferred to pre-cooled eppendorf tubes and spun at 13,000xg for 10 minutes at 4 °C. The
supernatants were quantified for protein concentration and 25ug of protein lysates were resolved
by gel electrophoresis and subjected to immunoblot analysis with antibodies specific for the
indicated protein.

II.2.5 Enzyme Linked Immunosorbent Assay
MDA-MB-231 mGFP and MDA-MB-231 ANGPTL4 mGFP cells were seeded in
100mm x 20mm plates for 24 hours. Then, the cells were rinsed three times with Phosphate
Buffered Saline (PBS) and grown in phenol red-free FBS in DMEM/F12 medium containing
0.02% of gentamicin for 48 hours. The amount of secreted ANGPLT4 in cell culture medium of
the respective cell lines were determined using a sandwich human ANGPTL4 ELISA kit
(Thermo Fisher Scientific) according to the manufacturer’s instructions.

II.2.6 Confocal Immunofluorescence Microscopy
MDA-MB-231 mGFP and ANGPTL4 mGFP cells were seeded at a density of 75,000
cells per well on glass coverslips inside a 24 well plate and grown for 48 hours. For GFP
expression the cells were fixed at room temperature with 4% Paraformaldehyde (PFA) in the
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dark, rinsed thrice with ice cold PBS and mounted with SlowFade™ Diamond Antifade
Mountant with DAPI (InvitrogenTM).

To stain for intracellular proteins, PFA was removed, and the cells on the coverslips were
permeabilized for 10 minutes in immunofluorescence (IF) buffer consisting of 2% BSA/PBS
with 0.2% saponin. The cells were rinsed in 2% BSA/PBS, incubated with primary antibodies
overnight. Next day the coverslips were incubated with secondary antibodies for 1 hour at room
temperature and rinsed three times (5 min each) in 2% BSA/PBS after each antibody incubation
(Bailey, et al., 2014).The coverslips were rinsed once with PBS and mounted on glass
microscope slides with SlowFade™ Diamond Antifade Mountant with DAPI
(InvitrogenTM).
All images were captured with a Leica confocal microscope and merged fluorescence pictures
were generated using Fiji-ImageJ.

II.2.7 Mammosphere Assay
The MDA-MB-231 mGFP and MDA-MB-231 ANGPTL4 mGFP cells were cultured for
7 days in Mammocult medium (STEMCELLTM Technologies) at 37 °C under 5% CO2 on ultralow attachment plates or flasks. The colonies were counted and imaged with an inverted light
microscope after 7 days. The mammospheres were used for immunoblotting and Oil Red O
staining. The p-value was calculated using student’s t test using graph pad software, USA.

II.2.8 Soft Agar Colony Formation Assay
1.25 x 103 MDA-MB-231 mGFP or ANGPTL4 mGFP cells were suspended in complete
medium with added 2ug/ml puromycin mixed with 3% noble agarose. The cells were seeded on
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the semisolid layer of complete medium and 0.6% noble agarose in six well plates at 37 °C under
5% CO2. Complete medium supplemented with 2ug/ml puromycin was added twice a week to
prevent drying-out of the agarose and to preserve moisture. The colonies were counted and
imaged using an inverted light Nikon Ti2 microscope after 7 days. The p-value was calculated
using student’s t test using graph pad software, USA.

II.2.9 Oil Red O staining
Mammospheres were stained with Oil Red O stain (60% 0.5% Oil Red O Solution in
40% ddH20) according to the manufacturer’s instructions. Fluorescent and brightfield
mammosphere colonies were counted and photographed with an inverted light microscope after
7 days.
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II.3 RESULTS
II.3.1 Generation and evaluation of ANGPTL4 expression in TNBC ANGPTL4 mGFP
overexpression cell line. MDA-MB-231 cells were transduced with either the plasmid containing
the empty vector or with the pLenti-C-mGFP-P2A-Puro plasmid with the ANGPTL4 gene.
ANGPTL4 mGFP was designated as the MDA-MB-231 ANGPTL4 overexpression cell line and
MDA-MB-231 overexpression empty vector control cell line referenced as MDA-MB-231 mGFP
(Figure 2.1A). Confocal microscopy showed the expression of mGFP expression in the control
and ANGPTL4 mGFP cell lines were used with DAPI to determine staining of the nucleus (Figure
2.1B). The genetically engineered cell lines mGFP and ANGPTL4 mGFP cells with strong
homogenous mGFP expression was determined by fluorescence microscopy and FACs was then
used for later experiments (Simeon J. (2017) Honors Thesis).
Western blot analysis of ANGPTL4 expression in MDA-MB-231 overexpression cell lines. Total
protein was extracted from the cell lines and immunoblotted with antibodies. This result confirmed
the expression of ANGPTL4 in the ANGPLT4 mGFP cell line and the lack of expression in the
MDA-MB-231 cell line transduced with an empty vector (Figure 2.1C, Lane 2).
ELISA Quantification of ANGPTL4 secretion by the transduced MDA-MB-231 overexpression
cell lines. The amount of ANGPTL4 secreted in culture medium by MDA-MB-231 overexpression
empty vector control and ANGPTL4 overexpression cell lines was assessed by an ELISA assay.
As shown in Figure 2.1D, the MDA-MB-231 ANGPTL4 overexpression cell line secreted
0.87735 ng/ml of ANGPLT4 in comparison to the MDA-MB-231 overexpression empty vector
control cell line secreting 0.022 ng/ml, n=3. This confirmed ANGPTL4 overexpression in the
respective cell line. The error bars indicate the standard deviation.
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Figure 2.1: Lentiviral-mediated transduction of MDA-MD-231 overexpressing ANGPTL4
confirmation. Map of lentiviral overexpression cloning vector, pLenti-C-mGFP-P2A-Puro
plasmid (A). Confocal images of the cell lines expressing mGFP in the cells mounted on
coverslips with DAPI for nuclear staining(B). Western blot analysis of ANGPTL4 expression
with a commercially available ANGPTL4 antibody and GAPDH as the loading control(C). The
amount of ANGPTL4 secreted by the cells measured by the ELISA kit (D) confirming that the
ANGPTL4 mGFP cell line is overexpressing ANGPTL4.
*Note: The lentiviral overexpression map image was adapted from Origene and reprinted from
Honors Thesis (Simeon, 2017).The Characterization of Angiopoietin-like 4 dependent Triple
Negative Breast Cancer Cells Extravasation using an in vitro model of the Human Blood Brain
Barrier. Honors College, Fulbright College, University of Arkansas.
*Note: This figure was reprinted from (Simeon, Thrush, & Bailey, Angiopoietin-like protein 4 is
a chromatin-bound protein that enhances mammosphere formation in vitro and experimental
triple-negative breast cancer brain and liver metastases in vivo, 2021). Journal of
Carcinogenesis.doi:10.4103/jcar. JCar20_
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II.3.2 The nuclear localization of chromatin bound ANGPTL4 and its association to Tip60
and AURKA
Subcellular fractions were accessed for intracellular localization of ANGPTL4 in TNBC
cells. ANGPTL4 is predicted to be in the nucleoplasm and potentially in the vesicles as seen in
the Human Protein Atlas database. So, to determine the intracellular localization of ANGPTL4 in
the MDA-MB-231 mGFP and MDA-MB-231 ANGPTL4 mGFP cells, subcellular fractionation
and intracellular staining were done. Subsequently, the cells from the respective cell lines were
imaged with confocal immunofluorescence microscopy. The nuclear localization of ANGPTL4
was confirmed (Fig 2.2A). TIP60 and AURKA are suggested to be interactors in the ANGPTL4
pathway as such, intracellular staining was conducted to evaluate the localization of TIP60 and
AURKA. TIP60 and AURKA was shown to colocalize in the nucleus of the MDA-MB-231
ANGPTL4 cell line and not in the MDA-MB-231 mGFP cell line (Fig. 2.2A). ANGPTL4 being
identified as a nuclear protein, was assessed in the chromatin lysate by immunoblot analysis to
see if it also localizes in the chromatin. ANGPTL4 was present in the chromatin lysate of the
MDA-MB-231 ANGPTL4 mGFP cell line and thus ANGPTL4 can be identified as a chromatin
bound protein (Fig 2.2B). Tip60 and AURKA was also evaluated by immunoblot analysis to see
if they were localized in the chromatin fractions. TIP 60 and AURKA was shown to localized in
the chromatin of the MDA-MB-231 ANGPTL4 mGFP cells (Fig 2.3B).
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Figure 2.2: Chromatin bound ANGPTL4, TIP60 and AURKA. Immunoflourscense microscopy
images of nuclear ANGPTL4, Tip60 and AURKA(A). Immunoblots depicting the presence of
TIP60, AURKA and ANGPTL4 in chromatin fractions(B).
*Note: This figure was reprinted from Simeon J, Thrush J, Bailey TA. (Simeon, Thrush, &
Bailey, Angiopoietin-like protein 4 is a chromatin-bound protein that enhances mammosphere
formation in vitro and experimental triple-negative breast cancer brain and liver metastases in
vivo, 2021)Journal of Carcinogenesis.doi:10.4103/jcar. JCar20_20
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II.3.3 MDA-MB-231 overexpressing ANGPTL4 cells promotes increased stem cell
formation

The MDA-MB-231 mGFP and ANGPTL4 mGFP cell lines were evaluated for stem cell
formation in mammocult media for 7 days. The number and the size of mammospheres
quantified were analysed with brightfield and flourscence microscopy. The number of MDAMB-231 ANGPTL4 mGFP mammospheres were significantly greater than the mGFP
mammospheres. The average number of mGFP and ANGPTL4 mGFP mammospheres that is ≥
200 µm is 0.75 um and 4.0 um, N=16 respectively. The quantity of mammospheres formed by
the ANGPTL4 mGFP is 63, while the mGFP cell line had 12, N=3. The error bars depict
standard deviation (Fig 2.3A). In terms of morphology, MDA-MB-231 mGFP cells formed small
compacted aggregrates compared to the larger loosely compacted aggregrates formed by the
MDA-MB-231 ANGPTL4 mGFP cells(Fig. 2.3B). Immunoblot analysis was done to evaluate
the presence of the CD44 and CD24 markers in the adherent and stem cell population of MDAMB-231 mGFP and ANGPTL4 mGFP cell lines. Mammospheres derived from the mGFP and
ANGPTL4 mGFP cell lines expressed smaller amounts of the CD24 marker compared to the
adherent cell lines. CD44 marker being expressed by both the adherent and mammospheres
mGFP and ANGPTL4 mGFP cell lines(Fig 2.3C). Oil Red O staining was used to analyze the
presence of triglycerides in the mGFP and the ANGPTL4 mGFP cell lines. The ANGPTL4
overexpressing cell lines retained more Oil Red O staining than the cell line expressing
endogenous levels of ANGPTL4 suggesting that there is more triglycerides in the ANGPTL4
mGFP cell line (Figure 2.3D).
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Figure 2.3: The formation of mammospheres in vitro from MDA-MB-231 mGFP and
ANGPTL4 mGFP cell lines. Graph showing the number of mammospheres ≥200 µm formed
from mGFP and ANGPTL4 mGFP cells lines, respectively (A). Brightfield images of primary
mammospheres formed in mammocult suspension resulting from the mGFP cell line and the
ANGPTL4 mGFP cell lines (B). Western blot analysis was performed to evaluate for the
presence of CD24 and CD44 stem cell markers in adherent (A) and mammospheres (M) cells
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Figure 2.3: (Continued) derived from MDA-MB-231 mGFP and ANGPTL4 mGFP cells (C).
Mammospheres formed from mGFP and ANGPTL4 mGFP cells stained with Oil Red O to
analyze the presence of triglycerides(D).
*Note: This figure was reprinted from (Simeon, Thrush, & Bailey, Angiopoietin-like protein 4
is a chromatin-bound protein that enhances mammosphere formation in vitro and experimental
triple-negative breast cancer brain and liver metastases in vivo, 2021) Journal of
Carcinogenesis.doi:10.4103/jcar. JCar20_20.
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II.3.4 Angiopoietin like protein 4 promotes anchorage independent growth
MDA-MB-231 mGFP and MDA-MB-231 ANGPTL4 mGFP cells were grown in media
containing 0.3% agarose to produce a semi-solid medium. The ANGPTL4 overexpression cell
line propagated more colonies than the mGFP cell line (Figure 2.4A). The average number of
colonies ≥200 um derived from the MDA-MB-231 mGFP and ANGPTL4 mGFP cells were 11
and 54 respectively, N=3. The combined average number of mGFP and ANGPTL4 mGFP
colonies ≥200um was 0.305, N=36 and 5, N=36 repectively. Error bars depict standard error. In
addition, brightfield and fluorescence microscopy shows that ANGPTL4 cells formed larger
loosely aggregated cells like the morphology of the MDA-MB-231 ANGPTL4 mGFP
mammospheres (Figure 2.4B).
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Figure 2.4: MDA-MB-231 mGFP and ANGPTL4 mGFP cells showed anchorage independent
growth. The number(A) and morphology (B) of colonies formed from mGFP and ANGPTL4
mGFP cells in 0.3% of agarose contaning medium shown using microscopy.
*Note: This figure was reprinted from (Simeon, Thrush, & Bailey, Angiopoietin-like protein 4 is
a chromatin-bound protein that enhances mammosphere formation in vitro and experimental
triple-negative breast cancer brain and liver metastases in vivo, 2021) Journal of
Carcinogenesis.doi:10.4103/jcar. JCar20_20.
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II.3.5 Discussion
To validate the role of intracellular ANGPTL4 expression in TNBC cell line,
immunofluorescence microscopy, immunoblot analysis, mammosphere and soft agar colony
formation assay can be used to determine the tumorigenic, anchorage-independence and invasive
ability of the ANGPTL4 primed MDA-MB-231 cell line. ANGPTL4 overexpression was
assessed and confirmed using immunoblot analysis, fluorescent microscopy, and an ELISA assay
for use in the following experiments.
Subcellular Fractionation, immunofluorescence microscopy and immunoblot analysis
were performed to evaluate the localization of ANGPTL4, TIP60 and AURKA. According to the
Human Atlas Protein database ANGPTL4 is predicted to be localized in the nucleosome and
possibly the vesicles, however the localization of ANGPTL4 has yet to be shown in TNBC cells.
ANGPTL4 was shown to localize in the nucleus and chromatin of MDA-MB-231 ANGPTL4
mGFP cells. This means that ANGPTL4 is a chromatin bound protein and could potentially
associate with DNA machinery in the chromatin. In addition, TIP60 and AURKA are possible
interactors in the ANGPTL4 pathway as such their localization was evaluated as well. TIP60 and
AURKA colocalized with ANGPTL4 in the nucleus and they were also present in the chromatin
of the ANGPTL4 overexpressing cells.
(McGuire, et al., 2019) evaluated that low Tip60 expression increases the risk of breast
cancer reccurrence. In this study, TIP60 enhances of the tumorigenic capability of ANGPTL4
mGFP cells due to the increased levels in ANGPTL4 overexpressing cell line. Tip60 is a known
to be involved in DNA damage response and transcriptional regulation (Gao, et al., 2014), (van
Beekum, et al., 2008), (Sapountzi, Logan, & Robson, 2006). Tip60 is necessary for DNA repair
via acetylation of the histones. In addition, Tip60 interacts with PARR, and it induces the
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regulation of PPAR gamma activity, which stimulates lipid metabolism which aids in cancer
progression (La Paglia, et al., 2017), (Li, et al., 2007), (van Beekum, et al., 2008). Therefore,
ANGPTL4 and tip60 may be working together to alter the transcriptional regulation of genes
associated with lipid metabolism or aid in DNA repair.
In this study, a mammosphere assay was performed to determine the ability of ANGPTL4
mGFP cells to form stem-cell enriched mammospheres. The mammospheres derived from the
ANGPTL4 mGFP cells were significantly greater in the size and number compared to the
mammospheres derived from the mGFP cell line. Additionally, immunoblot analysis showed that
the mammospheres consisted of low levels of the CD24 and proportionate levels of the CD44
stem cell markers compared to the adherent mGFP and ANGPTL4 mGFP cell lines. TNBC is
enriched with cancer stem cells compared to other breast cancer subtypes and shows CD44 high
and CD24 low phenotypes with self-renewal ability, enhances invasion and metastatic abilities
(Ma, et al., 2014), (Honeth, et al., 2008).
Oil Red O staining analyzed the presence of tricycerides in the mammospheres derived
from the mGFP and ANGPTLL4 mGFP cells. The ANGPTL4 mGFP had increased staining
intensity compared to the mGFP mammosphere cell line suggesting that there are elevated lipids
in the ANGPTL4 mGFP mammosphere derived cells. Obesity is a risk factor for breast cancer
and under obese conditions ANGPTL4 as a driver of cancer progression (Dietze, Chavez, &
Seewaldt, 2018), (Kolb, et al., 2019), (Sun, et al., 2017). A study reported that patients with an
upregulation of ANGPTL4 in uveal melanoma derived multicellular spheroids endured a
metabolic shift to suggesting that ANGPTL4 could potentially play a role in lipid metabolism
(Ness, et al., 2017).
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Anchorage independent growth of the mGFP and the ANGPTL4 mGFP cell lines were
evaluated using a soft agar colony formation assay. The ANGPTL4 mGFP cell lines propagated
larger and a greater number of colonies compared to the mGFP cell line. This suggests that
ANGPTL4 promotes anchorage independent growth of TNBC cells. (Zhu, et al., 2011) reported
that ANGPTL4 drives anchorage-independence and as a result promotes the ability of cancer
cells to evade anoikis and become resistance through activation of ROS in skin carcinoma cells.
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II.3.6 Conclusion
Cancer stems cells are known to make tumors more aggressive through self-renewal,
migration, and therapy resistance. The MDA-MB-231 ANGPTL4 mGFP cell line had an
increased number and growth of mammospheres formed in comparison to the mGFP cell line.
Also, the morphology of the mammospheres between the two cell lines were different. The
ANGPTL4 mGFP cells had bigger aggregates compared to the mGFP cell line. Therefore, that
data suggests that ANGPTL4 is a driver of mammosphere formation in the MDA-MB-231 cell
line. ANGPTL4 enhanced the anchorage independent growth of the MDA-MB-231 cell lines
compared to the mGFP cell line. The ANGPTL4 mGFP cells showed increased colony growth
and size similar to the mammospheres formed.
In addition, the results suggested that ANGPTL4 is localized in the nucleus of TNBC
cells and a chromatin bound protein. TIP60 and AURKA predictive interactors in the ANGPTL4
pathway were localized in the nucleus and chromatin of the ANGPTL4 cell line. TNBC cell line
overexpressing ANGPTL4 was shown to retain more of the Oil Red O staining than the mGFP
cell line expressing normal levels of ANGPTL4. This indicated that ANGPTL4 could potentially
alter the lipid profile of the cells. DNA damage consists of alterations in chromatin structure and
TIP60 is a chromatin-modifying protein and key component of repair. It also plays an important
role in antiproliferative responses to DNA damage and elicits such control via acetylation of
histones in the of DNA repair occurs. Additionally, TIP60 has a fundamental role in lipogenesis,
and proper modulation might be a promising strategy for the alleviation of cancer related obesity
and its associated metabolic diseases (Li, et al., 2018).
As stated, aberrant expression of AURKA may lead to genetic instability and cause
development of many cancers. It’s role in promoting tumor progression, such as the activation
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of epithelial–mesenchymal transition reprograms cancer cells stemness. Therefore, AURKA
could be a potential attractive target for cancer therapeutics in conjuncture with breast cancer
ANGPTL4 stemness phenotype. In conclusion, ANGPTL4 promotes tumor growth, formation of
large cellular colonies and tumor stemness of TNBC cells in vitro.

50

III. ANGPTL4 ENHANCES TUMOR GROWTH AND LIVER METASTASES IN VIVO
III.1 Introduction

After evaluating the role ANGPTL4 using in vitro assays, the overexpression of
ANGPTL4 in TNBC was evaluated via in vivo studies. Scientists have used in vivo models as
important research tools to study cancer initiation, invasion, and metastasis in a physiologically
relevant system in breast cancer research. This represents an essential step between in
vitro systems and clinical studies. In vitro studies may not account for all the interactions
between cells and biochemical processes that occur in the complexity of organ systems and thus
the use of animals in in vivo studies addresses many of the disadvantages of only using in
vitro studies (Tang, n.d.). In vivo studies also provide data that is important for validation of the
function or proof of concept and for evaluation of efficacy of a gene or drug in a complex model
(Vandamme, 2014). Moreover, advances in gene editing have helped scientists replicate human
diseases in animals with better accuracy (Lee, et al., 2020).
TNBC risk of distant recurrence peaks between 1 to 3 years after surgery and the time from
recurrence to death is 9 months, significantly shorter than other types of breast cancer. Triple
Negative Breast Cancer is associated with a higher rate of liver metastasis and, TNBC liver
metastasis is fatal to patients who have not undergone treatment, usually having 4-6 months of
survival before death (Kennecke, et al., 2010). To date, there are not many breast cancer mouse
models that are developed focused on the formation of liver metastases only. (Rikhi, et al., 2016)
established a murine model of direct injection of TNBC MDA-MB-231 cell line in the frontal
lobe of the liver, which the researchers were able to evaluate invasion and metastasis to the
lungs. (Lim, et al., 2020) established a liver-metastasis model of injecting TNBC from a patient
and implanting it on the liver lobe by doing a surgical hepatic incision, simulating liver
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metastasis. Using this model, they found lymph-node metastasis following liver metastasis
growth. In this study, a nude mice model was used to study liver metastasis. Nude mice are
athymic, so it makes them accepting of foreign cells which makes them great for cancer research,
understanding the mechanism of malignant tumors and testing potentially treatments
(Wettersten, Ganti, & Weiss, 2014), (Ito, et al., 2002).
ANGPTL4 is a factor that has been shown to aid in tumor progression, metastasis, and
invasion in a few human cancers. For these in vivo studies, the TNBC cell lines with the
endogenous and overexpression of ANGPTL4 were injected subcutaneously in athymic mice
and, the result of tumor growth and metastases was evaluated after a four-to-six-week period.
The primary tumors and major organs were harvested for further analysis. Tissue resection and
staining was done to determine the presence of ANGPTL4 and TIP60, in addition to Oil Red O
staining of the liver and tumor tissue.
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III.2 MATERIALS AND METHODS
III.2.1 Mouse human tumor xenograft model
All animal work was done in accordance with a protocol approved by the Institutional Care and
Animal Use Committee at the University of Arkansas. Immunocompromised female mice age
matched at four weeks old were used for xenografting studies. The mice were kept at the Central
Laboratory Animal Facilities (CLAF), where they acclimatized for one week prior the
experiment. The athymic mice were subcutaneously injected in the right flank with either the
MDA-MB-231 cell line or the ANGPTL4 mGFP cell line or PBS. The allotted number of mice
were held in a cage of dimensions 11.5”x 7.5’x5’ and was monitored once a day for physical
and/or neurological distress post injection until euthanasia. Tumor areas were measured every
three days using an electric caliper and were quantitated with the formula length multiplied by
the width (LXW). The mice were anesthetized four to six weeks post subcutaneous injection
with the cells, with isoflurane mixed with compressed air/oxygen. Primary tumors and organs
were harvested for tissue immunofluorescence imaging to identify GFP-positive tumors and
metastatic lesions. Two separate studies were conducted in which eight animals were used per
cell line in study one, and in study two six animals were used per cell line.

III.2.2 Whole Tissue Immunofluorescence Microscopy
Primary tumors and liver tissue was sectioned at 6.0 µm and stained for intracellular proteins.
Slices were fixed with 4% PFA, then the tissue slices were permeabilized for 20 minutes in
immunofluorescence (IF) buffer consisting of 2% BSA/PBS with 0.2% saponin. The tissue slices
were rinsed in 2% BSA/PBS, incubated with primary antibodies overnight and secondary
antibodies for 1 h at room temperature with three rinses (5 min each) in 2% BSA/PBS after each
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antibody incubation. After, the tissue slices were then rinsed thrice with PBS and mounted with
SlowFade™ Diamond Antifade Mountant with DAPI (InvitrogenTM).

All images were captured with a Nikon epifluorescence microscope in conjunction with NIS
Elements software to obtain fluorescent images at the indicated magnifications. Merged
fluorescence pictures were generated using Fiji-ImageJ.

III.2.3 Oil Red O staining
Primary tumors and liver tissue were stained with Oil Red O stain (60% 0.5% Oil Red O
Solution in 40% ddH20) according to the manufacturer’s instructions. Tumor and liver tissue
images were captured using a Nikon epifluorescence microscope in conjunction with NIS
Elements software to obtain brightfield and fluorescent images at the indicated magnifications.
Merged fluorescence pictures were generated using Fiji-ImageJ.
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III.3 RESULTS
III.3.1 ANGPTL4 drives primary tumor size and promotes TNBC metastasis to the liver

To evaluate tumorigenicity and the metastatic ability of MDA-MB-231 mGFP and
MDA-MB-231 ANGPTL4 mGFP overexpressing cell lines TNBC cells were injected
subcutaneously in the right flank of the athymic female mice for a 4 to 6-week period two
separate studies. The first study was conducted to evaluate liver metastasis in a 4-week period. A
second study was designed to evaluate if the results were reproducible. The mice were evaluated
over a 6-week period. The mice injected with the ANGPTL4 mGFP cells showed a greater mean
primary tumor size in comparison to the mice that were injected with mGFP cells. Photographs
showing tumor growth 4 weeks post injection of mice injected with mGFP and ANGPTL4
mGFP cells. In study 1, The mean primary tumor area derived from mGFP and ANGPTL4
mGFP cells were 3.14 mm2 and 20.32 mm2 respectively (Figure 3.1 A and B). In study 2, the
mean area of the primary tumor area derived from the mGFP and ANGPTL4 mGFP cells is 0
mm2 and 26.06 mm2 respectively, N=6. There was no area calculated for the primary tumor
formed from the injected mGFP cells because it was diminutive. (data not shown) (Figure 3.1 C
and D).
The weights of the mice injected with MDA-MB-231 mGFP and ANGPTL4 mGFP were
analyzed, however, there was not any significant difference in between the two sets of mice in
both studies conducted. The mean weight of the mice xenograft injected with mGFP cells and
ANGPTL4 mGFP cells was 25 and 24 g respectively in study 1 (Figure 3.2A). In study 2, the
mean weight of the mice xenograft injected with mGFP cells and ANGPTL4 mGFP cells was 23
g and 22 g respectively (Figure 3.2B). The brains, spleen, lung, kidneys, intestines, and livers of
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all mice were evaluated for mGFP-positive metastatic lesions. The organs containing no
metastases were not shown.
A comparison of the livers showed that seven out of the eight mice injected with
ANGPTL4 mGFP cell line developed liver metastases, compared to one out of the eight mice
injected with the MDA-MB-231 mGFP cell line developing metastasis (Figure 3.2C and D).
Additionally, there was no significant difference in the liver weights measured from the mice
injected with the MDA-MB-231 mGFP and MDA-MB-231 ANGPTL4 mGFP (Figure 3.2E).
The mean liver weight of the mice injected with the mGFP cells and the ANGPTL4 cells was
1276.15 mg and 1227.4 mg respectively. No metastatic lesions in the spleen, brains, spleen,
intestines, and lungs were reported.
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Figure 3.1: ANGPTL4 promotes tumor proliferation in vivo. Primary tumors were removed
from mice 4 weeks post subcutaneous injection with MDA-MB-231 mGFP and ANGPTL4
mGFP cells. Primary tumor photographs (A) and the mean tumor area (LxW) (B). In study 2, the
images of primary tumors were taken 4 weeks post subcutaneous injection with MDA-MB-231
mGFP and ANGPTL4 mGFP cells. Photographs of mice with primary tumors (C) and the mean
tumor area (LxW) (B)
*Note: This figure was reprinted from Simeon J, Thrush J, Bailey TA. (In Press).
Angiopoietin‑like protein 4 is a chromatin‑bound protein that enhances mammosphere formation
in vitro and experimental triple‑negative breast cancer brainand liver metastases in vivo. Journal of
Carcinogenesis.doi:10.4103/jcar. JCar20_20.
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Figure 3.2: Metastatic liver trophism derived from MDA-MB-231 mGFP cells and ANGPTL4
mGFP cells injected in a mouse xenograft. Mean weight of the mice collected before euthanasia
in both studies (A and B). Micrographs showing the number of metastatic lesions on the livers of
mice subcutaneously injected with MDA-MB-231 ANGPTL4 mGFP cells and the mGFP
cells(C). Table showing the number of metastases on organs removed from the mice injected
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Figure 3.2: (Continued) with mGFP cells and ANGPTL4 mGFP cells(D). Mean liver weight of
the mice collected after euthanasia (E).*Note: This figure was reprinted from Simeon J, Thrush
J, Bailey TA. (In Press). Angiopoietin‑like protein 4 is a chromatin‑bound protein that enhances
mammosphere formation in vitro and experimental triple‑negative breast cancer brainand liver
metastases in vivo. Journal of Carcinogenesis.doi:10.4103/jcar. JCar20_20.
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III.3.3 Immunofluorescence microscopy and Oil Red O Staining of tissue resected from the
mGFP and ANGPTL4 mGFP injected mice
GFP+ TNBC liver metastases were excised from liver tissue and assessed for the presence of
nuclear ANGPTL4, Tip60 and AURKA. No AURKA was detected (data not shown). ANGPTL4
was expressed in the nucleus of the liver tissue around the metastatic lesion and primary tumor,
immunofluorescence staining was done with ANGPTL4 antibody and imaged with
immunofluorescence microscopy. Experiments in vitro showed that ANGPTL4 colocalized with
Tip60, therefore, immunofluorescence analysis was done to evaluate if TIP60 is associated with
ANGPTL4 in the liver tissue and primary tumors. The slices were mounted with DAPI (nuclear
stain), and images were taken with a Nikon epifluorescence wide-field microscope. TIP60 and
ANGPTL4 was shown to compartmentalize in the nucleus in both tumor and liver tissue.
(Figure 3.3A)
Oil Red O staining of the primary tumor (xenografts) and liver tissue derived from the
mGFP and ANGPTL4 mGFP cell line evaluated for the presence of triglycerides was
comparable between the mice. The Oil Red O staining was proportional between the mGFP and
ANGPTL4 mGFP Liver and tumor tissue. (Figure 3.4B) Tissue slices were stained with 60%
0.5% Oil Red O Solution in 40% ddH20, counterstained with hematoxylin and imaged using a
Nikon epifluorescence wide-field microscope at indicated magnifications.
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Figure 3.5: Immunoflouresence microscopy showing the colocalization of ANGPTL4 and
Tip60(A). Oil Red O staining of the primary tumors and liver tissue from the mice injected with
mGFP and ANGPTL4 mGFP cells(B).
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Figure 3.5:(Continued) Immunoflouresence microscopy showing the colocalization of
ANGPTL4 and Tip60(A). Oil Red O staining of the primary tumors and liver tissue from the
mice injected with mGFP and ANGPTL4 mGFP cells(B).
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III.6 Discussion
The liver is a site of breast cancer metastasis, along with bone and lung (Berman, Thukral,
Hwang, Solin, & Vapiwala, 2013), (Hess, et al., 2006). Liver metastasis in TNBC patients results
in a poor prognosis (Bonotto, et al., 2014), (Gerratana, et al., 2015) and as median survival of
breast cancer patients with liver metastasis ranges from 4-6 months if left untreated. Thus, a
clinical need for a liver TNBC murine model is necessary to investigate the mechanisms used by
metastatic tumor cells and what can be used as a potential therapeutic option.
Currently, there a few mouse models to evaluate breast cancer liver metastasis with varying
results that pose their own challenges. The intrasplenic injection delivers tumor cells via the
splenic vein (Soares, et al., 2014). The intrasplenic injection minimizes the development of
simultaneous multi-distal metastasis which allows for the study of specific liver metastases.
However, the intrasplenic model requires the removal of the spleen splenic tumors, this
procedure that impacts immune function.
The most commonly used model of breast cancer metastasis relies on the intracardiac
injection which occurs by injecting tumor cells directly into the circulation via the tail vein or left
ventricle of the heart (Minn, et al., Genes that mediate breast cancer metastasis to lung, 2005),
(Kang, et al., 2003). Injection of the tumor cells result in bone, brain, lung, and liver metastasis,
including other organs (Basse, Hokland, Heron, & Hokland, 1988). Due to the multi distal organ
metastases, these mice frequently need to be euthanized before evaluating specific liver
metastasis preventing the ability to fully investigate metastatic growth within the liver.
Orthotopic injections of include the injection of tumor cells in the mammary fat pad of
immune competent hosts to assess subsequent metastasis (Aslakson & Miller, 1992), (Dexter, et
al., 1978). But the rate of liver metastasis from using this model, like the subcutaneous injection
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is very low compared to other metastatic sites such as the lung. The orthotopic and portal vein
injection results in liver metastasis after lung metastasis is established, complicating the need of
liver-specific metastasis (Aslakson & Miller, 1992), (Doornebal, et al., 2013).
Another murine model for cancer liver metastasis utilizes spontaneous metastasis in
genetically engineered mice. To date, reports of spontaneous murine models of breast cancer
metastasis that readily spread to the liver are not common and if they do develop it is in a low
percentage of mice (Derksen, et al., 2006), (Fantozzi & Christofori, 2006).
The portal vein injection model was developed to address the need for improved liver
metastasis models, that delivers tumor cells directly to the liver. This model delivers tumor cells
to the liver without complications of concurrent metastases in other organs or removal of the
spleen. Additionally, it represents an important tool to study breast cancer metastasis to the liver
and may be applicable to other cancers that frequently metastasize to the liver including
colorectal and pancreatic cancer.
The subcutaneous model used for this study is known as a spontaneous model for
metastasis. This model has its own advantages and disadvantages. A few strengths for using this
model are the metastatic disease development from tumor, site mimics human disease
progression and low cost. However, it’s only applicable to certain cell lines, asynchronous
metastatic development occurs, and the mouse microenvironment (Gómez-Cuadrado, Tracey,
Ma, Qian, & Brunton, 2017). (Munoz, et al., 2006) showed the subcutaneous model using MDAMB-231 cells usually metastasize to the liver, lung and lymph nodes.
To validate the role of ANGPTL4 in TNBC in vivo, subcutaneous injection was
conducted to determine tumorigenesis, invasiveness, and metastatic capability of ANGPTL4
overexpressing TNBC cells.
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ANGPTL4 drives tumor growth and TNBC liver metastasis. The MDA-MB-231 mGFP
and ANGPTL4 mGFP cells were injected subcutaneously into the murine model and after a 4–6week period the primary tumors (xenografts) and livers were resected. The mice injected with
the ANGPTL4 cell line had greater tumor area and number compared to the mGFP cell line. This
showed that ANGPTL4 is a driver of proliferation of the TNBC cells. ANGPTL4 enhances
proliferation of many human cancers including breast, bone, thyroid (Munoz, et al., 2006),
(Yang, et al., 2020), (Zhang, et al., 2012).

ANGPTL4 enhances liver metastasis of TNBC cells. Majority of the ANGPTL4 mice
developed liver metastasis, whereas only one mouse developed liver metastasis when injected
with mGFP cell line. ANGPTL4 is promotes cancer cell invasion and metastasis. ANGPTL4 has
been shown to prime breast cancer cells to disrupts the endothelial cell to cell junction of the
lung and brain parenchyma to invade and colonize these distal organs (Gong, et al., 2019),
(Padua, et al., 2008).

Additionally, TIP60 is localized with ANGPTL4 in the nucleus of the primary tumors
(xenografts) and the liver tissue resected around the metastatic lesion in the ANGPTL4 mGFP
mice. TIP60 regulates gene transcription and DNA damage response. Tip60 can also function in
cancer cell progression and metastatic ability of the cancer cells because of the epithelial and
mesenchymal transitions the cancer cells undergo to invading tissue.
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III.7 Conclusion
ANGPTL4 serves an important role in tumor cell motility, invasion, cell migration and
metastasis. It has also been reported to inhibit metastases in lung and gastric cancers by
preventing tumor progression and invasiveness (Chen, et al., 2018), (Tan, Teo, Sng, Zhu, & Tan,
2012). Conversely, ANGPTL4 expression seems to fluctuate in different human cancers such
oral, hepatocellular, colorectal, and renal cancer. Therefore, since ANGPTL4 doesn’t appear to
have a consistent role in its expression in tumors, there is currently no effective targeted therapy
against ANGPTL4 or standard molecular mechanism in which it aids tumor progression and
metastases in all human cancers.
In this study, the role of ANGPTL4 is evaluated in TNBC. The findings from this study
demonstrate that the overexpression of ANGPTL4 in TNBC cells is strongly associated with
increase growth, primary tumor formation and metastatic liver trophism in vivo.
Furthermore, the role of TIP60 and ANGPTL4 in the MDA-MB-231 cell line was also
assessed. The epithelial to mesenchymal transition is controlled by epigenetic modifications such
as histone acetylation. As mentioned, TIP60, a histone acetyltransferase that functions in DNA
repair relates to these transitions in cancer progression to tumour dissemination and high relapse
in breast cancer. Here, it is shown that ANGPTL4 is localized with TIP60 in the primary tumor
(xenograft) and liver tissue resected from the mice derived from the ANGPTL4 overexpression
cell line.
In this study, it has been demonstrated that ANGPTL4 promotes tumor size and
metastasis of TNBC cells.
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IV. FUTURE DIRECTIONS
TNBC liver metastasis standard treatment is chemotherapy with a high chance of
recurrence and increased incidences of death. Therefore, it is imperative to evaluate efficient
treatment options that may lengthen and increase the quality of life of TNBC metastatic patients.
One feasible area for favorable treatment strategy is exploiting the immune system to control
metastatic cancer in TNBC. Tumor-associated antigens can be recognized by the immune system
and evoke an immune response which may result in tumor cell death due to a T-cell tumorspecific response (García-Teijido, Cabal, Fernández, & Pérez, Tumor-Infiltrating Lymphocytes
in Triple Negative Breast Cancer: The Future of Immune Targeting, 2016). However, tumor cell
variants can evade the immune system by the activation of immune suppressive pathway and
escape immune destruction. As mentioned, TNBC is associated with high levels of tumor
infiltrating leukocytes and PD-L1 expression, supporting the investigation of immune checkpoint
inhibitors (Pelekanou, et al., 2018). As a result, developing new and precise molecular
biomarkers during prognosis would help to differentiate TNBC metastatic tumors because of its
heterogenous nature. Cancer biomarkers can monitor an individual’s risk of developing cancer in
a specific tissue such as the liver and a result develop an efficient alternative for treatment. In
addition, morphological and functional imaging technologies can also be used during in vivo
experiments which can track measurements of the metastatic biological processes.
The mouse model in this study of that can be used to evaluate effective therapies for
TNBC liver metastasis. This is important because patients with TNBC liver metastasis have poor
prognosis, and a high mortality rate. One advantage is that this mouse model is athymic as such
it expresses predominately macrophages. The dynamic function of macrophages was evaluated
as M1 macrophages being tumoricidal, whereas M2 macrophages promotes cancer (Mills, 2012),
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(Mills, Lenz, & Harris, A Breakthrough: Macrophage-Directed Cancer Immunotherapy, 2016).
ANGPTL4 is significantly expressed in macrophages and has shown to drive the polarization of
macrophages in colorectal cancer (Aryal, et al., 2016). Therefore, a future experiment would be
to evaluate immunotherapies that causes M1 polarization in the tumor immune
microenvironment of TNBC xenografts that overexpress ANGPTL4.
The current chemotherapy therapeutic strategies for the management of TNBC are
platinum compounds and taxanes targeting DNA repair complexes, taxanes for p53 and
anthracycline regimen for cell proliferation. TNBC is very aggressive and heterogenous subtype
of breast cancer. Though, TNBC responds well to chemotherapy, incidences of recurrence are
very high, and prognosis remains poor. (Verma, Provencher, & Dent, 2011) reported a treatment
review of TNBC patients undergoing treatment and evaluated that the first line for metastatic
treatment would be the standard chemotherapy drugs despite the current development of novel
targeted therapies.
TNBC metastatic patients with visceral metastases have a relatively shorter overall
survival have limited duration of response to successive lines of chemotherapy. So, it is
imperative to select the agents most likely to result in a more meaningful treatment and possibly
a longer overall survival. Therefore, because of TNBC biologically heterogenous nature,
identifying molecular biomarkers to predict response to specific chemotherapy is requred to
further improve treatment strategies with the current number of chemotherapy options and future
combinations with targeted therapies so patients can have a better overall survival.
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